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The mitochondrion is a vital component in cellular energy metabolism and intracellular signaling
processes. Mitochondria are involved in a myriad of complex signaling cascades regulating
cell death vs. survival. Importantly, mitochondrial dysfunction and the resulting oxidative and
nitrosative stress are central in the pathogenesis of numerous human maladies including
cardiovascular diseases, neurodegenerative diseases, diabetes, and retinal diseases, many
of which are related. This review will examine the emerging understanding of the role of
mitochondria in the etiology and progression of cardiovascular diseases and will explore potential
therapeutic benefits of targeting the organelle in attenuating the disease process. Indeed, recent
advances in mitochondrial biology have led to selective targeting of drugs designed to modulate
or manipulate mitochondrial function, to the use of light therapy directed to the mitochondrial
function, and to modification of the mitochondrial genome for potential therapeutic benefit. The
approach to rationally treat mitochondrial dysfunction could lead to more effective interventions
in cardiovascular diseases that to date have remained elusive. The central premise of this review
is that if mitochondrial abnormalities contribute to the etiology of cardiovascular diseases (e.g.,
ischemic heart disease), alleviating the mitochondrial dysfunction will contribute to mitigating
the severity or progression of the disease. To this end, this review will provide an overview of
our current understanding of mitochondria function in cardiovascular diseases as well as the
potential role for targeting mitochondria with potential drugs or other interventions that lead
to protection against cell injury.
Keywords: mitochondria, cardiac ischemia/reperfusion, cardiac metabolism, reactive oxygen species, nitric oxide,
peroxynitrite, mitochondrial Ca2+, therapy

Abbreviations: 5-HD, 5-hydroxydecanoic acid; ACC, acetyl-CoA carboxylase;
Acetyl-CoA, acetyl coenzyme A; ANT, adenine nucleotide translocase; CaU, calcium
uniporter; CK, creatine kinase; CPT, carnitine-acetyl-CoA (palmitoyl) transferase;
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Introduction
Mitochondria are abundant and dynamic organelles that not
only produce ATP for cellular function, but also participate in a
number of intracellular processes such as cell division, the initiation of mitochondrial signaling pathways, modulation of cytosolic
metabolic pathways, and modulation of cytosolic Ca2+ signals and
concentration, and ultimately determination of cell life or death. In
addition, mitochondria are a continuous source of superoxide anions (O2− ) and their reactive oxygen species (ROS) products (Stowe
and Camara, 2009; Camara et al., 2010b; Koopman et al., 2010),
particularly during cell injury. The rekindled interest in the organelle
is ascribed in part to its role as a “friend and a foe.” This “new” role
of mitochondria is crucial in understanding their utility as potential
targets for therapies in mitigating diseases process.
Overall cellular function is dependent on O2 consumption by
functioning mitochondria to produce energy with minimal electron
leak to generate O2− . Under physiological conditions, mitochondria
exist in a metabolic and cellular ion homeostatic state that is crucial
for normal myocardial function. Deviation from this physiological
set-point can result for example, in abnormally high mitochondrial
[Ca2+] (mCa2+) and increased oxidative stress. Oxidative damage to
mitochondrial membranes, enzymes, and electron transport chain
April 2011 | Volume 2 | Article 13 | 1

Camara et al.

(ETC) components culminate in impaired mitochondrial ATP production, which facilitates mitochondrial permeability transition
pore (mPTP) opening (Waldmeier et al., 2003) that leads to cellular
apoptosis and necrosis. Therefore, increases in mCa2+ and ROS
generation are two important underlying factors in the etiology
of many disease states, notably cardiovascular diseases including
heart failure, ischemia-reperfusion (I/R) injury, and other vascular
disease processes. A salient observation of mitochondria-related
diseases is that even though the fundamental pathological mechanisms remain unclear, there is much evidence that mitochondrial
dysfunction is a contributing factor at some level of every pathogenic process (Duchen, 2004).
It is evident then that knowledge of mitochondrial function in
normal and pathological states is crucial not only for our understanding of the basic cause of cardiovascular disorders, but also for
developing therapeutic strategies for attenuating a given disease
process. For example, attenuating electron transport, preventing
mPTP opening (Wenzel et al., 2008), or activating the putative mitochondrial K+ channels (mitoKATP and mitoKCa), are potential ways
to attenuate cardiac and vascular dysfunction by ameliorating the
underlying mitochondriopathic disturbances (Doughan et al., 2008;
Wenzel et al., 2008). The central premise of this review is simply that
if mitochondrial abnormalities contribute to a pathological state (i.e.,
directly or indirectly), then alleviating the mitochondrial dysfunction
should attenuate the severity or progression of the disease (Camara
et al., 2010b). Hence, the main objective here is to present a concept
that the mitochondria in all cells of the cardiovascular system can be
potentially targeted for therapeutic intervention in treating cardiovascular diseases. This attention is warranted because cardiovascular
diseases are a leading cause of death in the world. This review will
focus in Part 1 on basic mitochondrial biology and its integration
with the cytosol, metabolic regulation, structure and function, and
the emerging yet essential role of mitochondria in cardiovascular
disease in tandem with potential mitochondrial approaches for
intervention. Separate sections on selected mitochondria therapeutic approaches in specific cardiovascular maladies will be presented
in Part 2, followed by limitations and conclusions.

Part 1
Myocardial substrate metabolism and regulation –
integrating cell and mitochondrial function

Although this review emphasizes the important role of the mitochondrion in cardiovascular diseases and the emerging pursuit of
mitochondrial-directed therapies, it is reasonable to first describe
what is currently known about myocardial cell metabolism. Also, we
would be remiss not to summarize the pioneering work of several
research groups (Garland et al., 1963; Randle et al., 1963, 1970; Bing,
1965; Opie, 1965; Williamson, 1965, 1966; England and Randle,
1967; Bremer, 1969; Bremer and Wojtczak, 1972; Neely et al.,
1972; Oram et al., 1973; Neely and Morgan, 1974) who sought to
understand the mechanical/metabolic integration of the cytosolic
processes (energy use) with mitochondrial function (energy supply) during the basal cardiac state and during increases in cardiac
workload, hypoxia and ischemia.
It is well known that phasic contractility and relaxation are
dependent on the transient influx and efflux of Na+, K+ and Ca2+
to generate the action potential and trigger Ca2+ release from the
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sarcoplasmic reticulum (SR). The phasic increase and decrease in
[Ca2+] with each heartbeat precedes each contraction and relaxation
phase, which causes spikes in energy demand. How is this demand
met? We now typically divide cardiac energy metabolism into three
components (Neubauer, 2007) (1) substrate utilization [cell substrate
uptake and fatty acid (FA) breakdown by β-oxidation and pyruvate
by glycolysis yielding acetyl carbons on coenzyme A (CoA)], which
enters into the TCA cycle to produce NADH, FADH2, and CO2), (2)
oxidative phosphorylation (OxPhos, transfer of electrons from NADH
to O2 by respiratory complexes I–IV to create a proton motive force
required for ATP production at complex V, and (3) energy transfer and
utilization [translocation of matrix ATP via the adenine nucleotide
transporter (ANT) of the IMM and its conversion to phosphocreatine (PCr) for transfer to myofibrils where it is reconverted to ATP
by the creatine kinase (CK) energy shuttle system].
CK is a fast ATP-generating enzyme and a low-threshold sensor
for ADP (Wallimann et al., 1992). Because mycoplasmic PCr is
highly abundant, it serves as a temporal and spatial energy buffering transport system, which allows rapid ADP delivery for OxPhos
with an increase in workload and a rapid absorption of ATP when
workload decreases. Indeed the rate of ATP consumption is so
exquisitely linked to the rate of oxidative phosphorylation that
ATP, ADP, and PCr content remain nearly constant even when cardiac workload increases during intense exercise or catecholamine
release (Balaban et al., 1986). This suggested that consumption of
ATP did not directly control ATP synthesis.
The hypothesis that ATP, ADP, CrP, and Pi are not the primary
feedback regulators of OxPhos, e.g., during an increase in workload and O2 consumption, is based on numerous data that the
concentrations of these compounds do not change significantly
(Neely et al., 1972; Raymond and Potreau, 1977; Katz et al., 1989;
Balaban, 1990), i.e., the metabolic stability hypothesis. So alternatively it was proposed, and some data was provided, that (a)
increases in mCa2+ stimulate various rate – limiting TCA cycle
enzymes (Wan et al., 1989; McCormack et al., 1990), i.e., the Ca2+
stimulating hypothesis, (b) the PCr shuttle acts as temporal and
spatial buffers for the ATP hydrolysis potential, i.e., the PCr buffering
hypothesis (Saks et al., 2000), and (c) that the activities of enzymes
and transporters involved in ATP synthesis change in synchrony
with, and proportional to, changes in the rate of ATP utilization so
that perturbations can not be observed, i.e., the parallel activation
theory (Korzeniewski et al., 2005). The alternative hypothesis to the
metabolic stability hypothesis is of course that despite the negative
experimental data generated, organic phosphates and Pi indeed
regulate cardiac metabolism. Wu et al. (2007, 2008) developed a
computer model of cardiac energy metabolism that was able to
adequately simulate the data of Katz et al. (1989) but they arrived at
a different interpretation, i.e., that ATP synthesis is indeed feedback
controlled by an increase in the products of ATP hydrolysis (Beard,
2006; Beard and Kushmerick, 2009). The simulations also agree
with more recent experimental data (Ochiai et al., 2001; Zhang
et al., 2005). The point here is that all hypotheses are subject to be
disproven and alternate hypotheses should always be considered
and tested even if the null hypothesis appears dominant.
Acetyl-CoA is the 2-carbon donor derived from FA or from glucose oxidation. Complete β-oxidation of a 12-carbon FA produces
96 mol ATP compared to 72 or 76 mol ATP by glycolytic oxidation
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of a 12-carbon disaccharide. The different moles of ATP produced
by glycolysis depends on the use of the glycerol phosphate shuttle vs. the malate shuttle, respectively, which transfers reducing
equivalents from the cytosol to the matrix where they are oxidized
to produce energy. This transfer is slow and rate limiting in glycolysis so mitochondrial FA oxidation is much faster (Williamson
et al., 1976; Saks et al., 2006b). The major task of the TCA cycle is
to carry out the oxidation of the acetyl group of acetyl-CoA to CO2
and H2O with the subsequent production of reducing equivalents
to maintain the proton motive force and energy transfer from electrons to drive ATP synthesis.
Indeed, from earlier work (Williamson, 1965, 1966) it is now
well understood (Saks et al., 2006b) that during an increase in
workload, ATP production and respiration are increased due to
feedback signaling via the CK shuttle that leads to a decrease in
the mitochondrial content of acetyl-CoA. This decrease reflects
increases in the rates of respiration and NADH oxidation relative
to acyl-carnitine transport into mitochondria and β-oxidation. It
is now known that acetyl-CoA is transferred into the cytoplasm
during high workloads via the carnitine-acetyl carrier where it is
converted by acetyl-CoA carboxylase (ACC) to malonyl-CoA, an
important inhibitor of carnitine-acetyl-CoA (palmitoyl) transferase (CPT), and then converted back to acetyl-CoA by malonylCoA decarboxylase (MCD) during reduced workloads. Therefore,
an increase in workload increases the rate of acetyl-CoA consumption with a concomitant increase in malonyl-CoA content. This
mechanism prevents excess FA β-oxidation intermediates when
the workload decreases. This implies that malonyl-CoA is a feedback regulator of FA oxidation by allowing acyl-CoA entry into the
matrix only when it is needed (Opie, 1998). Thus the decrease in
malonyl-CoA (and increase in acetyl-CoA) is not the reason, but
rather the consequence of an increase in workload and FA oxidation (Saks et al., 2006b).
In broad terms this process of multiple feedback steps in regulating substrate utilization, OxPhos, and energy transfer and utilization at varying workloads, is called metabolic homeostasis, and
its study, metabolic control analysis. Identifying the specific rate
controlling reactions is cumbersome and typically carried out by
measuring depletion of substrates and accumulation of products
and their associated flux rates. Stanley et al. (2005) and Neubauer
(2007) have reviewed recently how substrates are metabolized by
mitochondria in the normal and failing heart. Metabolic Control
Analysis is a methodology that allows one to quantitate the control of flux and metabolites through a metabolic pathway (Kacser
and Burns, 1973; Heinrich and Rapoport, 1974; Fell, 1992). This
approach has been applied to a great variety of systems – from
bacteria to mammalian and plant cells – functioning at steady state
(Fell, 1996; Cortassa et al., 2002) but recently also to heart cells
and trabeculae under working conditions (Cortassa et al., 2009).
Cardiac metabolic control – historical perspective

Randle et al. (1963) long ago first recognized that cells utilize
either FA or glucose depending on substrate availability and that
the presence of FA markedly inhibits glycolysis; this is known as
the glucose–fatty acid cycle or the “Randle cycle.” It has been long
known that FAs contain more energy per mass unit than glucose
(Newsholm and Start, 1973). Neely et al. (1972) were among the first
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to recognize that increased cardiac work load was accompanied by
moderately increased glycolysis, marked fatty acid oxidation, and
enhanced TCA cycle turnover, but not by changes in PCr, ATP, ADP,
or 5′-AMP (later unequivocally verified by Balaban et al., 1986 using
NMR). Although perfusion of hearts only with glucose exhibited
marked pyruvate oxidation, those perfused with glucose+acetate
showed inhibited glycolysis and inhibited pyruvate oxidation. They
concluded that TCA cycle turnover was not solely dependent on
the availability of a given substrate but that the normally preferred
substrate was FA.
In a subsequent review, Neely and Morgan (1974) further
described the regulation of substrate utilization and energy
metabolism in the heart. They pointed out that the availability
of higher energy FA in aerobic perfused hearts suppressed lower
energy glucose utilization at several steps in the glycolytic pathway,
i.e., blocked glucose transport, inhibited hexokinase by its product
glucose-6-P, phosphofructokinase (PFK) by citrate (Garland et al.,
1963; England and Randle, 1967), and pyruvate dehydrogenase
(PDH) by acetyl-CoA and NADH (Bremer, 1969; Randle et al.,
1970). They described how FA uptake and oxidation are controlled by FA availability, the rate of acetyl-CoA oxidation (low energy
rates), and the rate of acyl translocation across the IMM (high
energy rates), which in turn is dependent on the activity of CPT.
They discovered that at higher workloads acetyl-CoA levels were
progressively decreased and concluded that FA oxidation becomes
limited (Oram et al., 1973); they suggested that acyl translocation and transfer to matrix CoASH or CPT activity, rather than
β-oxidation, was the limiting step to FA utilization. They discussed
how the NAD-linked dehydrogenase reactions of the TCA cycle
ultimately determine the rates of oxidation of both glucose and
FA and adjust the rate of utilization of each substrate to the availability of the other.
Although the preferred substrate for the heart was found to be
FA (80–100%), Neely and Morgan (1974) discussed that under
hypoxic or anoxic conditions the heart switches primarily from
FA to glucose; but under ischemic conditions the switch to glucose
is limited due to shortage of substrate. They also indicated that a
hypoxia/ischemia-induced rise in NADH inhibits glyceraldehyde3-P dehydrogenase thus restricting glycolysis. During I/R, diminished O2 supply for respiration and OxPhos leads to rapid decline
of ATP and PCr, and the concomitant increase in Pi, as a consequence of PCr hydrolysis, stimulate anaerobic ATP generation with
an increase in glycolysis and lactate production (Oram et al., 1973;
Wallimann et al., 1992). Whitmer et al. (1978) later reported that
decreased O2 delivery to the heart caused a fall in tissue content
of acetyl-CoA, acetyl-carnitine, CoASH, and carnitine, indicating
that β-oxidation becomes limited under these conditions. Thus
the heart has the ability to switch from FA to glucose oxidation
during anaerobic metabolism, which yields substrate (cytosolic)
level phosphorylation (2 mol ATP/mole glucose when pyruvate
is formed from phosphoenolpyruvate) on its pathway to form
acetyl-CoA.
In a 1979 review Williamson (1979) discussed how feedback
regulation from the TCA cycle and the respiratory chain to PDH is
likely determined primarily by alterations of the intra-mitochondrial NADH/NAD+ and acetyl-CoA/CoASH ratios acting separately
or in concert, and not by the intra-mitochondrial ATP/ADP ratio
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because this did not appear to change appreciably with changes in
cardiac activity, as noted by others. He noted that the malate shuttle is slow and limits maximal glucose oxidation. He additionally
described how the activities of NAD-linked TCA enzymes pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and isocitrate
dehydrogenase are regulated by the NADH/NAD+ ratio. As this ratio
decreases with increased workload, and the cytosolic ATP/ADP
ratio tends to fall and Pi to increase at the expense of PCr, respiration increases, thus increasing the flux of TCA cycle intermediates
(just enough acetyl-CoA enters the matrix (Saks et al., 2006b) with
increases in FA and/or glucose oxidation, which is highly regulated
by feedback mechanisms. There are other excellent older and newer
reviews (Bing, 1965; Williamson, 1979; Opie, 1998; Randle, 1998;
Nicholls and Fergunson, 2002) and original articles (Garland et al.,
1963; Williamson, 1965, 1966, 1979; England and Randle, 1967;
Bremer, 1969; Bremer and Wojtczak, 1972) that summarize and
update this seminal early work on cardiac metabolic homeostasis.
Mitochondrial DNA and protein transport as sites for
therapeutic intervention

Mitochondrial biogenesis and regulation of mitochondrial function result from a complex process that involves the coordinated
expression of both mitochondrial and nuclear genes (Camara et al.,
2010b). Much of the mitochondrial DNA (mtDNA) is used to code
for proteins that are key components of the energy-production
system. Indeed, mitochondrial DNA contributes 13 subunits to
ETC complexes. Cells depleted of mtDNA, called r0-cells, lack
some of the critical subunits of the ETC complexes, which result
in a defective respiratory system as evidenced by an insufficient
mitochondrial membrane potential (∆Ψm; Camara et al., 2010b).
The nucleus regulates numerous mitochondrial functions because
the nuclear DNA (nDNA) encodes a majority of mitochondrial
proteins. For example, complexes I and III are coded by the nDNA
and the mtDNA (Papa et al., 2008) whereas complex II is coded
only by nDNA. Several complex IV subunits, depending on the
tissue type, are also mitochondria-derived (Lenka et al., 1998;
Vijayasarathy et al., 1998). The mitochondrial proteins coded by
the nuclear genome promote increased synthesis of mitochondrial
encoded proteins and replication of mtDNA (Duchen, 2004). For
example, the nuclear respiratory factor-1 activates the transcription of a number of the nuclear-encoded components of the ETC
and also regulates mitochondrial transcription factor A, which is
responsible for the transcription of mtDNA-encoded genes (Csiszar
et al., 2009b).
Nuclear-encoded proteins targeted for mitochondria are
imported by a complex system of import proteins (TOM and
TIM, outer and inner membrane translocases, respectively). Import
of nuclear-encoded proteins or precursor peptides relies on the
proper function of the mitochondrial protein uptake machinery.
A coordinated protein import system is important for mitochondrial maintenance and biogenesis and any disruption can lead to
cell dysfunction and demise, including cells in the cardiovascular
system (Duchen, 2004). The protein import pathway has been used
to direct proteins into mitochondria based on specific targeting
sequences (Schapira, 2006). A defect in a specific protein or damage
to the import system can contribute to other defects in mitochondrial function and underlie at least some cardiovascular disorders.
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Therefore, knowledge of mitochondrial protein import is likely
key to understanding the molecular mechanisms of many disease
states, and it also opens the possibility of therapeutic intervention
by targeting the imported proteins or their translocases.
Outer mitochondrial membrane as a target for potential
therapeutic agents

The elaborate structure of a mitochondrion is important for its normal functioning, so its structural elements are potential therapeutic
targets. Each mitochondrion consists of two specialized membranes
dividing the organelle into a narrow intermembrane space (IMS)
bordered by the outer mitochondrial membrane (OMM) and the
inner mitochondrial membrane (IMM) that encloses the matrix
(Figure 1). The OMM is a relatively simple phospholipid structure
permeable to small molecules and ions; it contains many proteins
including monoamine oxidase (MAO) and the voltage dependent
anion channel (VDAC).
The OMM is also a major source of ROS and MAO (mostly
the A isoform), with a large presence in the OMM, contributes to
the ROS generated by mitochondria under pathological conditions. The MAOs are mitochondrial flavoenzymes that catalyze
the oxidative deamination of catecholamines and biogenic amines,
like dopamine, and serotonin (5-HT). In the process, ROS (H2O2
from O2−) is generated (Kaludercic et al., 2010a,b), which exert
hypertrophic effects or aggravate I/R injury (Kaludercic et al.,
2010a; Nediani et al., 2011). During I/R or heart failure, the heart
is exposed to chronic neuro-hormonal or peripheral hemodynamic
distress and this leads to elevated circulating catecholamines, resulting in MAO-induced ROS production. In the heart, it has been
reported that 5-HT accumulates during I/R and contributes to
the progression of myocardial damage and injury independent of
5-HT receptor mediated activity (Bianchi et al., 2005), and in the
kidney MAO-induced H2O2 production during dopamine degradation was reported to mediate cell apoptosis (Bianchi et al., 2005).
A possible mechanism for MAO-mediated cell death is that MAOdependent ROS generation induces an increase in the Bax/Bcl-2
ratio and mitochondrial cytochrome c release, leading to cardiac
cell apoptosis (Bianchi et al., 2005). In a recent study, Kaludercic
et al. (2010b) reported that in addition to 5HT, NE catabolism
by MAO plays a prominent role in cardiac hypertrophy. In their
study, Kaludercic et al. (2010b) reported that MAO enhanced NE
metabolism in transverse aortic constriction in mice, which was
also associated with exacerbated oxidative stress, chamber dilation,
and reduced systolic function. These observations provide evidence
for the pivotal role that mitochondrial MAO has in these disease
processes and provides a therapeutic potential for their inhibition.
The targeting of mitochondrial MAO for its potential therapeutic
effect derives in part from the finding that MAO inhibition can
counteract oxidative stress and mitochondrial-induced cell death
while reducing myocardial damage due to I/R injury (Bianchi et al.,
2005; Morin et al., 2009).
The VDAC is a principal site for the exchange of metabolites
between the IMS and the cytosol. The VDAC is a regulated conduit
that provides an access route into the IMS for ions and a variety of cellular metabolites such as ATP and ADP (Okada et al.,
2004). Decreased phosphorylation of VDAC, which is induced
by inhibition of glycogen synthase kinase, can reduce ATP entry
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Figure 1 | The figure shows the basic structural components of the ETC
complexes (I, II, III, IV, and V) the sites of proton pumping after electron
transfer from complex I and complex II during mitochondria substrate
oxidation, that leads to the generation of ATP. Fatty acid oxidation and
Krebs cycle generate NADH and FADH2 needed to energize mitochondria
and establish the mitochondrial membrane potential (∆Ψm; −180 to
−200 mV). The ∆Ψm can be modulated be uncoupling proteins (UCP).
Phosphate is imported and exported through the adenine nucleotide
translocase (ANT) and this is one way to regulate matrix phosphate levels.

into mitochondria (Das et al., 2008). As a major gateway in and
out of the mitochondrion, VDAC mediates an intimate dichotomy between metabolism and cell death (Ujwal et al., 2008). The
mitochondrial-mediated cell death pathway involves an array of
OMM and cytosolic proteins that include the hexokinases (I and II),
the 4-chlorodiazepine (CDZ) sensitive peripheral benzodiazepine
receptor (PBR), and the Bcl-2 protein family that alternatively promote or prevent cell injury (Bryson et al., 2002; Pastorino et al.,
2005; Pastorino and Hoek, 2008; Ujwal et al., 2008). Specifically,
PBR interacts with mPTP through VDAC and regulates apoptosis as
it blocks the anti-apoptotic effect of Bcl-2 family proteins (Kroemer
et al., 2007). CDZ reduces ischemia-induced arrhythmias and cytochrome c release independent of mPTP opening by inhibiting PBR
(Camara et al., 2010b). Perfusion of rat hearts with a cell-permeable
peptide corresponding to the BH4 domain of Bcl-XL, which is
reported to close VDAC and to prevent the VDAC-mediated release
of cytochrome c, was shown to inhibit CK release and to reduce
myocardial cell death (Morin et al., 2009). Thus the OMM supports protein-to-protein interactions between the anti-apoptotic
and pro-apoptotic proteins.
The hexokinase (HK)-VDAC is another OMM protein-to-protein interaction that offers an intriguing target to selectively provide
cytoprotection against oxidative damage. Accumulating evidence
has shown that HK translocation to mitochondria plays a crucial

www.frontiersin.org

Targeting mitochondria in cardiac ischemia

Substrate uptake is mediated through mitochondrial inner membrane (IMM)
proteins [e.g., carnitine palmitoyl transferase (CPT) and pyruvate
dehydrogenase (PDH)]. Ca2+, which may modulate mitochondrial respiration
is taken up via the calcium uniporter (CaU). Other components of the IMM
include the putative transporters/exchangers. These include the Na+/H+
exchanger (NHE), the K+/H+ exchanger (KHE) and the Na+/Ca2+ exchanger
(NCE), some of which have been characterized. The putative Ca2+/H+
exchanger (the so-called Na independent Ca exchanger or NICE; not shown)
is considered a likely regulator of ion flux dynamics.

role in promoting cell survival, when needed, and to instigate its
removal if cell death is required, as in cancer cells (Camara et al.,
2010b). Indeed, in malignant tumor cells, unlike normal cells, elevated oncogenic kinase signaling favors the binding of HK to VDAC
by Akt-dependent phosphorylation of HK (Pastorino et al., 2005).
Enhanced association between HK and VDAC provides protection
against permeabilization of the OMM and resistance to apoptosis (Galluzzi et al., 2008; Pastorino and Hoek, 2008). However, it
is noted that the binding to the VDAC is not a prerequisite for
HK binding to OMM because the enzyme binds to OMM in yeast
strains that are deficient in VDAC (Shoshan-Barmatz et al., 2008).
Nonetheless, a possible therapeutic strategy that targets mitochondrial metabolism involves enhancing HK–VDAC interactions.
For example, it was reported that closure of VDAC by HK prevents
mPTP opening and blocks apoptosis (Azoulay-Zohar et al., 2004).
Other studies show that increased HKII binding to VDAC prevents the pro-apoptotic Bcl-2 family proteins from binding to the
OMM, and so helps to promote, for example, cancer cell survival
(Costantini et al., 2000; Gogvadze et al., 2009; Mathupala et al.,
2009). Indeed, HK is frequently overexpressed in some human
tumors and it binds to VDAC more tightly in cancer cells than in
their normal cell counterparts (Pastorino et al., 2005). This protection may be prevented, as a therapeutic approach, by adding
3-bromopyruvate, an inhibitor of HK activity and HK binding to
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mitochondria, the latter most likely by preventing the HK-VDAC
interaction (Pedersen et al., 2002; Chen et al., 2009). In non-malignant conditions, partial knockout of HKII has been associated with
increased cell death in a mouse model of cardiac I/R injury (Smeele
et al., 2010). For the heart it is suggested that the mitochondriaHK interaction is indeed an integral part of cardioprotection
because many cardioprotective interventions, such as ischemic
preconditioning (IPC) and anesthetic preconditioning, increase
mitochondria-HK binding (Zuurbier et al., 2009). The translocation and increased binding of HKII to cardiac mitochondria can be
invoked in the mechanism of cardioprotection by IPC and opioids
(Smeele et al., 2010). HKII binding to mitochondria to decrease
pro-apoptotic Bcl-2 family protein binding to OMM, as well as
decreasing ROS production may contribute together to improving
mitochondrial and cell function during reperfusion after ischemia.
Taken together, these studies suggest that the mitochondrial HK
interaction plays a key role in promoting cellular survival; thus targeting its binding to the mitochondrion may offer a novel strategy
to potentiate the efficacy of other modes of cardiovascular intervention. A mitochondria-targeted therapy designed for the OMM
as a potential therapeutic maneuver is highly relevant and is the
subject of intense research. An understanding of the interaction
between the cytosolic proteins, glycolytic or apoptotic, and the
OMM should help to optimize therapies for treating degenerative
diseases, including ischemic heart disease and heart failure. These
mitochondrial related diseases and the potential targeting of the
organelle as a mitigating factor will be discussed in detail in the
coming sections.
Inner mitochondrial membrane and matrix as sites for
potential therapeutic agents

The IMM is convoluted into a large number of infoldings called
cristae. As a consequence, the IMM has a large surface area that
increases the efficiency of the chemical reactions that take place
at its inner surface (Koopman et al., 2010). The IMM is relatively
impermeable and allows only certain small molecules (ions mostly)
to pass through. The major phospholipid component of the IMM,
cardiolipin, is intimately involved in several mitochondrial bioenergetic functions as well as in the regulation of cytochrome c content
and function. IMM proteases, by targeting mitochondrial fusion
proteins (discussed below), also regulate the release of cytochrome
c release from mitochondria (Frezza et al., 2006). Apoptosis inducing factor (AIF) is also released from the IMM, but by proteolytic cleavage catalyzed by mitochondrial calpain and preceded by
mitochondrial ROS emission (Norberg et al., 2010). I/R mediated
cell death can be prevented by calpain inhibitors and by MnSOD
(Norberg et al., 2010). Damage to cardiolipin has been implicated
in numerous pathological conditions, including cardiovascular
abnormalities. Paradies et al. (2009) reported that cardiolipin
content observed in mitochondria from I/R hearts paralleled the
fall in complex I activity.
Cardiolipin and cytochrome c can form into a complex called
cytochrome c-cardiolipin peroxidase, which under oxidative stress
and oxidation of cardiolipin can lead to the release of cytochrome
c and other pro-apoptotic factors from the IMS to the cytosol
(Chen et al., 2010). Therefore, targeting this complex, as demonstrated with nitric oxide (NO), has proven somewhat valuable in
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protecting against oxidation of cardiolipin, and as a result helps
to preserve cytochrome c (Vlasova et al., 2006). Indeed, in a comprehensive study, Vlasova et al. (2006) reported that NO acts as
an effective inhibitor of peroxidase activity on the cytochrome
c-cardiolipin complex, and in this way preserves cardiolipin integrity. The authors observed that NO acted as an effective inhibitor
of the peroxidase activity of cytochrome c without significantly
altering the cardiolipin molecule itself. Similarly, the dominant
antioxidant effect of NO on the peroxidation reaction catalyzed
by myoglobin and hemoglobin is reduction of oxo-ferryl reactive species (Gorbunov et al., 1995). This observation along with
those by Shidoji et al. (1999) showed that cardiolipin peroxidation
products resulted in a lack of effective binding of cytochrome c
to cardiolipin. This suggests that reducing the catalytic peroxidase activity of the complex by NO reduces the hydroperoxide
products that enhance peroxidation of the lipid. It is therefore
likely that NO prevents the oxidation of cardiolipin in part by
inhibiting the damaging effects of the peroxidase activities of the
cytochrome c-cardiolipin complex that occurs during ischemia
and other oxidative stress. Thus, inhibiting the peroxidase activity of the complex may be a pathway by which NO attenuates
cardiolipin oxidation (Shidoji et al., 1999); it is also reported that
NO could be an effective scavenger of peroxyl and other radicals
(Chamulitrat, 2001). These observations indicate that the cytochrome c-cardiolipin peroxidase complex is an important factor
in oxidative-mediated damage and represents a viable option to
be considered in targeting mitochondria therapeutically.
The adaptor protein p66Shc is an IMS protein located in the ETC
segment between complex III and IV. The regulation of p66Shc is not
fully understood. At physiological states, the protein is silent but is
activated in response to pro-apoptotic stimuli. Recent studies have
shown that p66Shc is involved in e− transfer with reduced cytochrome
c, and so it can modulate ROS production and the cardiovascular
oxidative stress response (Shoshan-Barmatz et al., 2008; Camara
et al., 2010b). Mitochondrial p66Shc can be induced, for example,
by hypertrophic stimuli and it is a signaling link between cellular stress and mitochondrial apoptotic activity (Guo et al., 2009).
Activation of the protein occurs via H2O2 dependent phosphorylation of the Ser36 residue, with its ultimate translocation to mitochondria. Once in mitochondria, p66Shc also alters mCa2+ handling,
and ultimately can induce apoptosis (Pinton et al., 2007). In addition to stimulating release of ROS, p66Shc can decrease MnSOD
expression levels by activating the Akt-dependent phosphorylation
of Forkhead transcription factor (FOXO3a) pathway, a regulator
of MnSOD expression. Consistent with these mechanisms, mice
deficient in mitochondrial p66Shc genes display increased levels of
FOXO3a, and decreased ROS production and decreased cardiac
I/R injury (Carpi et al., 2009; Di Lisa et al., 2009).
It was proposed recently that the therapeutic targeting of ETC
complex IV as a strategy to mitigate I/R injury may worsen outcome
in part because of the increased levels of reduced cytochrome c
(Chen et al., 2010), a substrate for p66Shc mediated ROS generation.
It is possible that pharmacological therapies that inhibit mitochondrial p66Shc expression or action may act as panacea for clinical
disorders characterized by increased oxidative stress, e.g., atherosclerosis, I/R injury and cardiac heart failure. However, Di Lisa et al.
(2009) noted in a recent review that at present the translation of
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experimental findings into the clinical realm is limited by the lack
of drugs that might be effective against a direct p66Shc mediated
ROS production.
The IMM also contains the adenine nucleotide translocator
(ANT), which along with VDAC, is believed to play a role in the
formation, or more likely, the regulation of the mPTP. The ANT
has been shown to be a prominent target for oxidative and nitrosative stress and so appears to be an important component in
mitochondria-related cell death and diseases. ANT interacts with
both the anti-apoptotic and pro-apoptotic BCl-2 protein families,
which then act as allosteric modulators of the ATP/ADP anti-porter (Marzo et al., 1998; Brenner et al., 2000; Belzacq et al., 2003).
Another potential binding partner of ANT is mitochondrial creatine kinase (mCK), which together with other enzymes is part of a
phosphotransfer network that is crucial for the coupling of OxPhos
with ATP-consuming processes (Saks et al., 2006a). Enhancing
phosphotransfer from ATP to creatine in close proximity to ANT
may be beneficial in preventing mPTP opening and reducing ROS
production under stress conditions (Dolder et al., 2003; Meyer et al.,
2006). The underlying mechanism may be the result of conformational changes in ANT and a more state 3 like respiration due to
increased ADP production. A therapeutic approach could involve
the design of creatine analogs that would increase the turnover
of ATP to ADP in proximity to ANT. Disruptions of ANT activity, on the other hand, can result in inhibition of ATP/ADP antiporter activity, excess ROS production, cytosolic ATP depletion,
and mitochondria depolarization and apoptosis (Don et al., 2003).
Clinically, dysfunction of ANT has been proposed to be involved
in dilated cardiomyopathy (Dorner et al., 1997). Thus, preserving
ANT functional integrity may provide a unique opportunity for
pharmacological or molecular genetic maneuvers that target this
protein to preserve mitochondrial function during cell injury.
Under physiological conditions, mitochondria exhibit a high
IMM potential (∆Ψm) that is initiated by proton pumping from
the matrix with simultaneous e− transfer along the ETC; ∆Ψm is
also maintained by various cation channels and exchangers that
regulate cation fluxes. The trans-membrane cation movement
through specialized cation transporters and exchangers are therefore essential for creating the resulting mitochondrial bioenergetic
state (Figure 1). Mitochondrial cation anti-porters/exchangers
(H+-linked) regulate the osmotic differential across the IMM. This is
necessary in part because of a low cationic permeability and a strong
H+ electrochemical gradient that is established by e− transfer and
cation exchangers to prevent osmotic overload; these conditions are
necessary for efficient OxPhos (Camara et al., 2010b). The transmembrane cation movement through specialized cation transport
and exchangers is therefore essential for creating the resulting mitochondrial bioenergetic state (Figure 1).
Alterations in the dynamic regulation of ion fluxes underlie
numerous abnormalities of mitochondrial related function. For
instance, mCa2+ uptake through the Ca2+ uniporter (CaU) is largely
dependent on ∆Ψm. This mCa2+ uptake may have profound consequences for mitochondrial function, such as altering cellular respiration and mediating cell death by apoptosis or necrosis (Sack,
2006a; Camara et al., 2010b). A small increase in mCa2+ during
increased workload is thought to be necessary for activating TCA
cycle enzymes to furnish the reducing equivalents necessary to
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match energy demand with supply (Camara et al., 2010b). However,
high m[Ca2+], as observed during cardiac I/R, can impair ATP synthesis and lead to a loss of ion homeostasis, stimulation of ROS
generation, mPTP opening, matrix swelling, and OMM rupture
(Jones et al., 2003; Teshima et al., 2003b). Cumulatively, all these
factors result in collapse of ∆Ψm, release of signaling molecules
(cytochrome c, AIF, and Smac/Diablo), and exacerbation of ROS
production, resulting in a catastrophic vicious cycle of mitochondrial functional decline, and ultimately cell death (Brookes et al.,
2004; Muravchick and Levy, 2006). This subject matter along with
the role of other mitochondrial proteins intimately involved in
regulating mitochondrial free ion concentrations and matrix pH,
have been discussed extensively in our recent comprehensive review
article (Camara et al., 2010b).
It is important to note that the ∆Ψm is about two times larger
than the sarcolemmal membrane potential. This provides a unique
chemical opportunity for selectively targeting the mitochondrion
for therapeutic purpose. In fact, this unique attribute of mitochondria has been employed to direct the so-called “mitochondriotropic” drugs to target the matrix (Brookes et al., 2004). For
example, Smith et al. (1999) reported that complexing vitamin
E with the triphenyl-phosphonium (TPP+) cation augmented
mitochondrial uptake of the complex. The cationic metalloporphyrin superoxide dismutase mimetic Mn (III) meso-tetrakis
(N-ethylpyridium-2-yl) porphyrin (MnIII TE-2-Pyp5+) has been
shown to accumulate in mitochondria derived from mice cardiac
myocytes following systemic injection (Spasojevic et al., 2007). We
have shown that mitochondrial superoxide (O2− ) production and
heart damage resulting from prolonged cold I/R was attenuated
when the permeant MnSOD mimetic manganese (III) tetrakis
(4-benzoic acid)porphyrin (MnTBAP) was perfused into the coronary arteries along with catalase and glutathione (GSH) before
ischemia (Camara et al., 2010b). However, the effectiveness of
these drugs to mitigate cardiovascular abnormalities in the clinical
setting has yet to be determined.
Mitochondrial permeability transition pore opening as a
potential therapeutic target

A key aspect of mitochondrial involvement in cell demise is control
of the opening of the mPTP. Crompton et al. (1987) were the first
to report that mPTP opening plays a crucial role in myocardial I/R
injury. The mPTP is a highly dynamic, non-selective pore for which
the precise structural identity is not well defined. Suffice it to state,
however, that the pore is thought to span the OMM and the IMM
and that it mediates the lethal permeability changes of the IMM and
OMM that leads to cell apoptosis. The mPTP may allow limited and
transient passage of electrolytes, small molecules, and metabolites.
But irreversible opening of the pore leads to release of apoptotic
protein factors (Kim et al., 2003; Martinez-Ruiz et al., 2008; Sun
et al., 2008), and a loss of NAD+ results in impaired capacity to
restore redox signaling and O2− scavenging (Di Lisa et al., 2001). A
detailed description on the putative constituents and functionality
of the pore, physiological or pathophysiological, has been discussed
in our recent comprehensive review article (Camara et al., 2010b)
and so will not be discussed further here. Indeed, mPTP opening is
especially sensitive to oxidative stress since it is favored by decrease
in NADPH/NADH and GSH/GSSG ratio (Di Lisa et al., 2009).

April 2011 | Volume 2 | Article 13 | 7

Camara et al.

As noted above, recent evidence suggests that at low c onductance
states the pore might contribute to the exchange of small metabolites between the cytosol and matrix, a process that is mainly controlled by mitochondrial solute carriers (Fulda et al., 2010). In this
case the opening of the pore is considered a “physiological valve,”
which alleviates mCa2+ overload, for example, as a consequence
of a brief surge of Ca2+ within a localized microdomain of the
mitochondria–endoplasmic reticulum (Smaili and Russell, 1999)
(Figure 2). Mitochondria play an essential role in buffering physiological loads of Ca2+ upon insult, whereas the mPTP provides a
fast Ca2+ extrusion mechanism in response to excessive levels of Ca2+
(Sareen et al., 2007). In addition, the brief opening and closing of
the pore (flickering) are implicated in providing protection against
cellular injury (Kindler et al., 2003). This dual role of the mPTP in
the survival and death of the cell will therefore be critical in selective
targeting of the pore for therapeutic interventions.
Pathologically, mPTP opening is initiated by excess mCa2+,
enhanced ROS production, and increased Pi. Adenine nucleotides,
Mg2+, and matrix H+ restrict the pore from opening (Brookes et al.,
2004; Duchen, 2004; Halestrap et al., 2004, 2007; O’Rourke, 2007).
It is proposed that I/R promotes mPTP opening in two phases: (i)

Figure 2 | Interaction between mitochondria and SR Ca2+-release channels.
This structural arrangement allows mitochondria and SR to be connected by tether
proteins (not shown), which allows regulation of matrix Ca2+ that may modulate
mitochondrial activity. Mitochondria take up Ca2+ ions entering the cytosol from
internal stores (SR) of the local “microdomain” via signaling molecules that include
Ca2+ and ROS. After cell stimulation, inositol 1,4,5-trisphosphate (IP3) and cADP
ribose (cADPr) release calcium from SR through their respective receptors [IP3R
and ryanodine receptors (RyR)]. Local increases in cytosolic Ca2+ concentrations
are buffered by mitochondrial uptake through the calcium uniporter (CaU) and
possible alternative routes, such as the putative Ca2+/H+ exchanger [the so-called
Na+ independent Ca2+ exchanger (NICE, or CHE); not shown]. Intra-mitochondrial
Ca2+ may activate synthesis of reduced substrates (NADH) by metabolic pathways
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mPTP priming during ischemia occurs as a progressive IMM leak
and is accompanied by depressed ETC function in the setting of FA
accumulation and loss of cytochrome c and ROS scavengers; and (ii)
the triggering of mPTP at reperfusion as determined by the interplay of ∆Ψm with rising mCa2+, with ROS and matrix H+ (Honda
et al., 2005). During ischemia pore opening is minimized, but on
reperfusion conditions such as increased matrix Ca2+, Pi, and ROS
favor long-lasting pore opening. Sustained and prolonged opening
of the mPTP can lead to excessive H2O entry into the matrix, matrix
swelling, and increased OMM permeability (via oligomerization
of Bid or Bax) or rupture of the OMM and IMM. Figure 3 summarizes the deleterious changes in mitochondrial function during
and after cardiac I/R associated with mPTP opening, permeabilization of the OMM, and changes in bioenergetic state associated with
individual components of mitochondria that are potential targets
for therapeutic intervention.
As noted the exact molecular composition of the mPTP remains
elusive and mysterious. The previous model structure of the mPTP
put forward by Halestrap (2010) and Di Lisa and Bernardi (2006)
involves the combination of the ANT in the IMM, the VDAC in
the OMM, and the regulatory protein cyclophilin D (CypD) in the

and accelerate the electron transport chain (ETC); a resulting increase in ROS
production may in turn facilitate Ca2+ release by sensitization of IP3R and RyR. The
increase in respiration is associated with enhanced proton pumping and
subsequently increase state 3 respiration with perhaps increase CHE activity so
that more Ca2+ is taken up from the localized “microdomain.” Other putative
mechanisms that increase ROS generation are modifications of ETC complexes
by mCa2+ and inhibition of the ETC by nitric oxide (NO). The NO can be increased
by Ca2+-induced NO synthase. Mitochondrial can also support Ca2+ release by
efflux via Na+/Ca2+ exchange (NCE). The delicate balance in the regulation of Ca2+ in
the “microdomain” is crucial in the pathology of mitochondria-related
cardiovascular complications. Reproduced and modified by permission from
Camello-Almaraz et al. (2006).
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Figure 3 | Simplified schema of changes in cytosolic and mitochondrial
function during cardiac I/R injury and site of mitochondrial-targeted
therapies with potential to reduce mitochondrial and cell damage. Targets
are (a) the outer mitochondrial membrane (OMN), (e.g., putative mPTP
components VDAC, ANT, etc.); (b) the inner mitochondrial membrane (IMM),
[e.g., ANT, Ca2+ uniporter (CaU), Na+/Ca2+ exchanger (NCE), Ca2+/H+ exchanger
(CHE)]; (c) the membrane potential (∆Ψm); (d) electron transport (complexes I–V);
and (e) ATP synthesis/hydrolysis (complex V). Abbreviations: ETC, electron
transport chain; SLP, substrate level phosphorylation; ROS, reactive oxygen

matrix (Camara et al., 2010b). In addition, a benzodiazepine receptor, HK, and mitochondrial mCK are thought to act as regulatory
components of the pore (Honda et al., 2005). Associated with the
outer leaflet of the IMM, in the IMS, is the CK. As mentioned earlier,
mCK, under physiological conditions, is crucial in catalyzing the
transphosphorylation of creatine by ATP to phosphocreatine and
ADP. In apoptotic-induced cell death, mCK may facilitate contact between VDAC and ANT to form the pore at the contact site
between the IMM and the OMM (Muravchick and Levy, 2006).
Interestingly, recent studies have provided evidence that exclude
the ANT and VDAC as components of the mPTP. For example,
genetic knockout studies showed that mPTP opening could occur in
the absence of VDAC and ANT; nevertheless, they could both play
a regulatory role. VDAC plays a critical role in the maintenance of
mitochondrial function, and ultimately preserves cellular function,
while ANT appears to function as a Pi and Ca2+ sensitive mPTP
regulator. IPC protection could be mediated by the phosphorylation and inhibition of GSK-3β, a downstream target of Akt, thereby,
inhibiting mPTP opening in part by binding to ANT (Nishihara
et al., 2007). CypD was first identified as ANT-binding protein that
mediated the inhibitory effect of cyclosporin A (CsA) on mPTP.
The role of CypD in the regulation of cell survival or death is evidenced by the finding that cells lacking the Ppif gene that encodes
the protein are protected from necrotic caspase-independent cell
death, but not from caspase-dependent apoptosis (Kim et al., 2003;
Baines et al., 2005; Basso et al., 2005).
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species; RNS, reactive nitrogen species; mPTP, membrane permeability
transition pore; ANT, adenine nucleotide translocator; VDAC, voltage dependent
anion channel. Compounds: VAs, volatile anesthetics; CDZ, chlorodiazepine; HK,
hexokinase; CGP, CGP37175: DNP, dinitrophenol; MnTBAP, Mn(II)tetrakis(4benzoate) porphyrin chlorine; CsA, cyclosporin A; NIM811, N-methyl-4isoleucine-cyclosporin; SS, Sezto–Schiller tetrapeptides; SFA, sanglifehrin; LRT,
lipid replacement therapy; CCCP, carbonyl cyanide p-(trifluoromethoxy)
phenylhydrazine, MnTMPyP, Mn(III)tetrakis[(1-methyl-4-pyridyl)-porphyrin]; IF1,
inhibitory factor 1; CO, carbon monoxide; NIRL, near infrared light.

Prolonged opening or a large conductance of the pore has been
associated with numerous pathological conditions, e.g., stroke
accompanied by brain ischemia (Matsukawa et al., 2009). These
actions of the mPTP apply in most instances of cell damage and
suggest that pharmacological agents, or any other maneuvers that
minimize pore opening, might minimize the extent of permanent
damage that arises. For example, Pravdic et al. (2010) reported
recently that in vivo isoflurane-induced post-conditioning prevented mPTP opening in part by mild inhibition of mitochondrial respiration, depolarization of mitochondria, and acidification
of matrix pH. These events may lead to better preservation of
mitochondrial bioenergetics and minimize Ca2+ overload and cell
death (Pravdic et al., 2010). Another example is that melatonin, a
well-known antioxidant, has also been shown to protect against
reperfusion injury by inhibiting mPTP opening (Petrosillo et al.,
2009) (Figure 3). In this case, mitochondria isolated from rat hearts
exposed to melatonin before I/R were less sensitive than mitochondria isolated from control I/R hearts to mPTP opening as
demonstrated by their resistance to Ca2+-induced pore opening.
CsA, the well-known inhibitor of mPTP opening, had effects similar
to melatonin (Petrosillo et al., 2009).
In a recent limited human clinical trial it was suggested that
CsA can reduce infarct size and improve recovery of contractile
function on reperfusion (Gomez et al., 2009). The antidepressant
drug nortriptyline was also reported to exert its neuroprotective
effects against cerebral I/R injury in part by delaying mPTP opening
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secondary to resisting Ca2+ overload (Zhang et al., 2008). Similarly,
the derivative of CsA, NIM811, and the non-immunosuppressive
sanglifehrin (SFA) inhibited mPTP opening (Theruvath et al.,
2008; Figure 3) and prevented cytochrome c release. In this way
it is thought that normal e− transfer to complex IV (see below)
and the scavenging potential of cytochrome c (discussed below) is
also preserved. A clinical trial reported that targeting mPTP with
post-conditioning or CsA at the moment of angioplasty improved
contractile function and reduced cell death in patients with acute
myocardial infarction (Ruiz-Meana et al., 2010). These studies do
provide some encouragement for a clinical approach to delay or
prevent irreversible mPTP opening. It is obvious that our understanding of the structural components and activity of the pore are
crucial in our attempts to pharmacologically target the pore as
a potential site for therapy (Figure 3). It is thus noteworthy that
achieving control of the mPTP during the disease process is an
important goal from the perspective of minimizing the early loss
of functional and structural integrity, and for maximizing salvage
following the initial injury.
Therapeutic potential of interfering with electron
transport chain and oxidative phosphorylation

The IMM contains enzyme complexes and transport systems that
are important in the transduction of energy from substrates that
provide for the normal functioning of the cell. Under aerobic
conditions, the ETC complexes allow proton translocation, and in
the process, function to convey e− along and down a redox potential (Stowe and Camara, 2009; Lenaz and Genova, 2010; Lenaz
et al., 2010). Electrons are transferred from NADH and FADH2
from complex I and II, respectively, to downstream redox centers
(Figure 1). The complexes are thought to be dispersed randomly in
large groupings called respirasomes or supercomplexes, which are
held in place by cardiolipin and which are functionally connected
to coenzyme Q and cytochrome c (Stowe and Camara, 2009; Lenaz
and Genova, 2010; Lenaz et al., 2010). The supercomplex is thought
to improve the efficiency of OxPhos by eliminating the diffusion of
substrates and products between individual complexes (Paradies
et al., 2009). The ubiquinone moiety is redox active, accepting two
e− and two H+ in its reduction to ubiquinol (James et al., 2005).
Concomitant to the e− transport, H+ ions are pumped from the
matrix into the IMS (Figure 1). The energy released during the
process is efficiently utilized to phosphorylate ADP to ATP by translocation of H+ from the IMS to the matrix through complex V (F1/
F0 ATP synthase; Stowe and Camara, 2009; Camara et al., 2010b).
Hence OxPhos results in transient dissipation of ∆Ψm.
Cardiomyocytes, like neurons, depend almost entirely on
OxPhos for their function. Therefore, structural preservation of
the ETC complexes/supercomplexes is paramount in maintaining
a high bioenergetic status to provide efficient cellular homeostasis
with minimal ROS production (Camara et al., 2010b). In fact, mitochondrial defects encompassing complex I–IV of the ETC likely
characterize a large number of human diseases (Cohen and Kesler,
1999a,b), at least in part. In a recent preliminary study, we reported
that cardiac I/R disrupted the supercomplex structures and that
ranolazine, a late Na+ channel blocker and an anti-anginal drug,
preserved the integrity of the complexes following I/R (Gadicherla
et al., 2010). This preservation of the mitochondrial supercomplexes
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by ranolazine, after I/R, was associated with improved f unctional
recovery and more normalized mitochondrial bioenergetics in the
isolated beating heart (Aldakkak et al., 2009).
Indeed, the targeting of mitochondrial ETC complexes to achieve
cardioprotection has become an attractive approach compared to
other remedies for protection against cardiac injury. For example,
amobarbital and volatile anesthetics attenuate complex I activity,
diazoxide reduces complex II activity, and hydrogen sulfide attenuates complex IV activity (discussed below and shown in Figure 3).
Because of the abundance of mitochondria in cardiomyocytes, these
mitochondria represent a major source of O2− (discussed below);
on the other hand, mitochondria are also major targets of ROS.
Therefore the successful targeting of mitochondrial complexes for
a therapeutic purpose is in part ascribed to the vulnerability of the
complexes and cardiolipin to oxidative stress (Paradies et al., 1997;
Lesnefsky et al., 2001).
A defect in several of the respiratory complexes can be considered a potential source or inducer of O2− during I/R. Paradies
et al. (2004, 2009) reported that a decrease in complex I activity,
as observed in I/R hearts, was associated with a decrease in state 3
respiration. Others have coined the name “complex I syndrome” in
which complex I inactivation is associated with protein nitration
and oxidative damage to mitochondrial proteins and phospholipids (Navarro and Boveris, 2009). On the other hand, a limitation of e− transfer during ischemia to complex III, a major source
of O2− , represents a new concept to limit mitochondrial damage
specifically during I/R (Lesnefsky et al., 2001; Chen et al., 2006,
2008; Aldakkak et al., 2008a). In fact, we observed that attenuating
complex I activity (e− flux) with the reversible inhibitor amobarbital protected the heart, and mitochondria in particular, from I/R
injury when the drug was present only during ischemia (Aldakkak
et al., 2008a). A recent study by Chen et al. (2010) showed that
amobarbital given before ischemia preserved mitochondrial respiration in isolated mitochondria with glutamate and TMPDascorbate, whereas sodium azide inhibition was not protective.
The authors inferred that a specific region in the ETC, most likely
between complex III and IV, leads to mitochondrial damage during
ischemia (Chen et al., 2010). Although the Qo site of complex III
is implicated in most of the ROS during I/R, Chen et al. (2010)
postulated that the protection by antimycin A against I/R injury
indicates that the specific site that elicits mitochondrial damage
during ischemia is likely located in the segment between complex
III and complex IV.
Other strategies for targeting the mitochondrial complexes have
potential to be worthwhile approaches. For example, Hanley et al.
(Hanley et al., 2002, 2003; Hanley and Daut, 2005) reported that
the putative mitoKATP channel opener diazoxide may protect against
I/R injury in part by inhibiting complex II, which could lead to less
e− transfer to complex III and decrease reverse e− flow to complex I,
and in the process minimize O2− generation. In contrast, Wojtovich
and Brookes (2009) reported recently that atpenin, believed to be
a specific complex II inhibitor, increased post-ischemic recovery
and decreased infarct size in a mitoKATP (blocked by 5-hydroxydecanoate) channel sensitive manner. The authors observed that
although atpenin interacts with complex II, it had no direct effect to
decrease complex II activity and that it is indeed a potent mitoKATP
channel activator (Wojtovich and Brookes, 2009). Thus, the benefit
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of targeting the mitochondrial ETC or membrane channels is that
it provides an alternative approach to cardioprotection against I/R
injury (Chen et al., 2007; Nadtochiy et al., 2007).
The structural integrity of the IMM is equally important in
maintaining mitochondrial function to achieve normal and efficient
OxPhos. As noted above, cardiolipin, a lipid high in unsaturated
fatty acids content, is highly susceptible to oxidative and nitrosative
stress (Armstrong, 2008). The loss of ETC complex activities has
been ascribed to degradation of cardiolipin. For example, cardiolipin dysfunction can lead to impaired complex V activity, which
would lead to impaired ATP levels, to a derangement of cellular
ion homeostasis, and eventually to cell death. In a brain anoxia and
reoxygenation model, mitochondrial lipid peroxidation, cardiolipin damage and cytochrome c release, and collapse of ∆Ψm, were
observed in isolated mitochondria, independent of mPTP opening
(Morin et al., 2003b). Thus therapeutic targeting of cardiolipin
is a reasonable alternative approach. Indeed, lipid replacement
therapy (LRT) has gained significant traction recently as a therapeutic approach to restore mitochondrial membrane integrity and
function as a means to mitigate oxidative damage (Figure 3). LRT
involves actual replacement of damaged lipids of cellular and mitochondrial membranes. Fusion of mitochondria from I/R hearts,
which contain lower levels of cardiolipin, with liposomes containing cardiolipin restored cardiolipin levels and preserved complex
activities (Paradies et al., 2009). The restoration or preservation of
the integrity of the IMM, specifically its cardiolipin content, is likely
to be beneficial in restoring cardiac function. Overall, these studies
highlight an emerging paradigm that restoration of mitochondrial
structural integrity may improve ETC efficiency and hinder activation of apoptotic mechanisms.
As alluded to before, mitochondrial electrophysiology is crucial
in determining whether there is mitochondrial function or dysfunction. An increase in K+ flux via the putative mitoKATP channel may lead to an increase in matrix volume and may result in
more efficient ATP synthesis (Garlid et al., 2003) and better cellular
preservation. In a recent study (Stowe et al., 2006) we provided
novel evidence for a regulatory role of the putative mitoKCa on
mitochondrial function and its cardioprotective value against I/R
injury. Mitochondrial ROS scavengers abolished the cardioprotection implying a key role of ROS in activation of the putative mitoKCa
channel-mediated cardioprotection. Putative activation of mitoKATP
channels, for example with diazoxide, which as noted above has
other effects on mitochondria, also has cardioprotective effects;
preventing mCa2+ overload and subsequently preserving ∆Ψm are
considered as possible mechanisms (Teshima et al., 2003a). The
implications for the involvement of mitochondrial channels and/
or exchangers in cellular damage portend a potential therapeutic
utility in the management of ischemic disease states.
Therapeutic potential of uncoupling proteins

Uncoupling proteins (UCPs), which are integral membrane proteins located in the IMM (Figure 1), are important physiological
regulators of mitochondrial function and redox potential; thus
UCPs are also regulators of O2− production. Uncoupled OxPhos
results from e− transfer and H+ influx into the matrix independent
of ADP phosphorylation (Sack, 2006b). UCPs stimulate mitochondrial respiration by partially dissipating the H+ gradient across the
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IMM, which tends to destabilize ∆Ψm. Excessive ROS accumulation
commonly occurs in state 4 respiration due to the high electrochemical gradient and limited e− transfer. One of the effects of
UCPs is to prevent buildup of ROS by partially dissipating the
∆Ψm (Teshima et al., 2003a; Sack, 2006b). The physiologic role of
uncoupled respiration is best exemplified by the adaptive thermogenesis induced by UCPs in brown fat. Because UCPs are capable
of reducing mitochondrial ROS formation by modulating ∆Ψm
(Haines et al., 2010), they have an impact to reduce the damaging
effects of ROS during cardiac I/R or hypoxia injury (Fiskum et al.,
2004; Barreiro et al., 2009).
There are four UCPs variants (1–4) believed to induce inward
H+ leak in energized mitochondria (Jezek et al., 1998; Stuart et al.,
2001; Brookes, 2005; Stowe and Camara, 2009) (Figure 1) and
thereby to uncouple OxPhos. This uncoupling is well established
for UCP1 with its central role in thermogenesis whereas the functions of the other isoforms are still being debated. UCP2 and UCP3
are present in the heart and provide some cardioprotection (Sack,
2006b). Knocking out UCP2 increased brain damage after middle
cerebral artery occlusion (Haines et al., 2010). Other studies show
that UCP2 overexpression is inversely correlated with caspase-3
activation in neurons (Deierborg et al., 2008). In rat neonatal
cardiomyocytes, UCP2 overexpression confers tolerance to oxidative stress via diminished mCa2+ uptake and reduced ROS production (Sack, 2006b). Some lipid peroxidation products, such as
4-hydroxy-trans-2-noneal (HNE), may induce partial uncoupling
of mitochondria through UCPs and are thereby also reported to initiate protective mechanisms (Boss et al., 1997; Echtay et al., 2003).
It is worth repeating that during myocardial I/R injury or heart
failure an increase in catecholamine concentration activates FA
utilization in cardiomyocytes by β-oxidation. With increased
β-oxidation there is a concomitant increase in mitochondrial
ROS, but gene expression of UCPs is also activated so that tends
to reduce ∆Ψm and ROS production. So it is interesting that chronic
treatment with trimetazidine, which partially blocks β-oxidation
in the matrix, has been shown to mitigate ischemic or heart failure
disease (Ashrafian et al., 2007), but this may be counterintuitive
as β-oxidation furnishes more energy per carbon than glycolysis.
In a recent study we (Heinen et al., 2007) suggested that a small
H+ leak brought on by the putative mitoKCa channel opening NS1619
in cardiomyocytes led to ROS production without substantially
changing ∆Ψm. It is possible that this “mild” uncoupling may contribute to the protection of the heart against I/R injury as shown by
NS1619 (Stowe et al., 2006). We showed that the NS1619-induced
protection in isolated hearts was mediated by preservation of mitochondrial redox state, reduced mCa2+ loading, decreased deleterious
ROS production, and better functional recovery; this protection
was abolished when hearts were treated either with MnTBAP, an
antioxidant, or paxilline, a KCa channel antagonist (Camara et al.,
2010b). It has also been suggested that mitoKATP channel openers
(Murata et al., 2001) and volatile anesthetics (Sedlic et al., 2010a,b)
are cardioprotective by virtue of inducing a “small amount” of
ROS production and mild uncoupling of mitochondria (Figure 3).
In addition to stimulating UCPs to ameliorate pathological ROS
production and protect against oxidative injury, there is the potential therapeutic use of low doses of artificial uncouplers to target the
mitochondrion. One such drug is the protonophore dinitrophenol
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(DNP), which has been utilized to treat obesity (Camara et al., 2010b).
However DNP, if used in excess can markedly reduce ∆Ψm, so its
low therapeutic index limits its utility as a viable therapeutic option
(Blaikie et al., 2006). Similarly, low concentrations of carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazine have been reported to protect by preventing mPTP opening (Teshima et al., 2003b) (Figure 3).
Taken together, these findings suggest that a better knowledge of the
ionic mechanism of H+ leak by UCPs and synthetic uncouplers could
provide the basis for better design of mitochondriotropic drugs to
reduce cellular injury following oxidative stress. Indeed, animal studies of heart failure and transgenic mouse models have suggested that
UCPs may be important in the endogenous response of heart muscles
to oxidant stress and that UCPs may be a potential target for heart
disease therapy (Laskowski and Russell, 2008).

Figure 4 | Principal mechanisms for mitochondrial reactive oxygen species
(ROS) generation. Reduced substrates synthesized in metabolic pathways
supply e− to complex I and complex II of the ETC. The major centers for
superoxide (O2−) formation are complex I and complex III, although small amounts
may also be formed at complex II and complex IV (omitted for clarity). The
electron carrier of complex III ubiquinone (Q) is reduced to ubiquinol (QH2), which
transfers an electron to cytochrome c (Cy C) through a Fe protein (not shown)
inhibited by myxothiazol (Myx). The resulting semiubiquinone (Q•) is oxidized back
to ubiquinone by cytochrome b (Cy b), and can also transfer e− to O2 to form O2− .
Myx reduces O2− production because it blocks Q• formation, whereas antimycin A
(Ant A) enhances it by increasing Q• levels. The drug rotenone (Rot) inhibits
electron flow distal to O2 generation, enhancing its production. The O2− generated
by Myx and Ant A are topographically oriented, whereas the O2− generated by
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Targeting mitochondrial ROS and RNS generation as
potential therapies

In this and the subsequent section, ROS (O2− , H2O2 and OH , etc.)
and RNS ( NO and ONOO−, etc.) generation and scavenging will
be discussed. Under the physiologic state, “small amounts” of
O2− are formed during mitochondrial respiration, but which are
maintained at acceptable levels by endogenous matrix antioxidant
defenses (Tsutsui et al., 2006) (Figure 4). A “small amount” of ROS
is important in normal cellular function. In excitable tissue, especially cardiac and neuronal, mitochondria represent a major source
of O2− as a consequence of large mitochondrial numbers and a
high level of OxPhos (Cadenas et al., 1977; Cadenas and Davies,
2000; Andreyev et al., 2005). H2O2, a relatively inactive compound, is
generated from dismutation of O2− , and in a Fe-dependent Fenton

Myx are directed to the matrix where they are scavenged; O2− generated by Ant
A are released into the IMS and so escape the powerful matrix scavengers. The
figure also depicts the dismutation of ROS and the reaction O2− and NO to
generate ONOO−. A better understanding of the topographical sites of O2−
generation and the role it would have in a disease process could be important in
targeted scavenging of ROS to mitigate or prevent the initiation or progression of
a particular-mitochondria-related dysfunction and cardiovascular abnormalities.
Modified reproduction with permission (Camello-Almaraz et al., 2006). SOD,
superoxide dismutase; H2O2, hydrogen peroxide; ONOO−, peroxynitrite; NO ,
nitric oxide; ∆Ψm: mitochondrial potential; AS, ATP synthase; OMM, outer
mitochondrial membrane; IMM, inner mitochondrial membrane; GSH and GSSG
reduced and oxidized glutathione, respectively; GPX, GR and CAT glutathione
peroxidase, glutathione reductase and catalase, respectively.
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reaction, it generates the toxic radical group Fe=O• (Stowe and
Camara, 2009). When administered on reperfusion the Fe chelator
desferrioxamine was found to improve function during cardiac I/R
(Lesnefsky et al., 1990; Dobsak et al., 2002; Liachenko et al., 2003).
Many more recent observations indicate that the targeting of
mitochondrial O2− as a therapeutic goal in cellular dysfunction
requires a careful balancing of the “good” (physiological) and “bad”
(pathological) O2− . Small amounts of ROS have been implicated
in pre- and post-conditioning cytoprotection as evidenced by the
loss of protection in the presence of scavengers (Stowe and Camara,
2009; Camara et al., 2010b). When ROS production exceeds the
capacity of detoxification and repair pathways, oxidative damage
to proteins, DNA (mtDNA and nDNA), and membrane lipids such
as cardiolipin occurs. In post-mitotic cells the continuous accumulation of oxidative damage triggers the accumulation of nonfunctional mitochondria, a process that could lead to mitochondrial
autophagy. These conditions can culminate in impaired ATP generation and cell death (James et al., 2005). Hence, mitochondrial
ROS generation and oxidative damage are potential targets (Figure
3) to apply pharmacological and molecular approaches for therapeutic interventions (James et al., 2005) as discussed in detail below.
Although O2− is generated from several sources in the mitochondrion, the main source of mitochondrial O2− appears to be within
the IMM of the ETC, in particular at complexes I and III (Turrens
and Boveris, 1980; Cadenas and Davies, 2000; Chen et al., 2003,
2007). However, the specific sites and mechanisms of O2− generation remain unsettled (Turrens et al., 1985; Ambrosio et al., 1993;
Babcock and Varotsis, 1993; Chen et al., 2003). In intact mitochondria from normal hearts, ROS are formed from complex I when
e− flux is backward from complex II, or at the ubisemiquinone site
of complex III (Camara et al., 2010b), where a radical intermediate
is formed through the Q-cycle of the complex, particularly at the
Qo site (Figure 4). Indeed experiments have shown that complex
III generates O2− through the oxidation of ubisemiquinone, which
faces the IMS, while complex I mediated O2− generation is directed
mostly toward the strongly scavenging matrix side (Chen et al.,
2003, 2007, 2008).
In cardiac I/R injury, impaired complex I can enhance O2−
generation as a result of increased e− leak as e− transfer is impeded
(Camara et al., 2010b). When FADH2 related substrates are used
and an e− enters the ETC at complex II, O2− may be generated by
reverse e− transfer to the FMN site of complex I (Chen et al., 2007;
Zoccarato et al., 2007; Stowe and Camara, 2009). Although complex
I is a site for O2− generation (Chen et al., 2008), complex III may
become a major site for O2− generation (Chen et al., 2008) in cardiac
cells under ischemic conditions. Ischemia damages complex III by
functionally altering the Fe–S protein subunits (Chen et al., 2007).
As will be discussed, an increase in O2− emission (O2− generation
−
– O2 -scavenging) under pathological conditions can also occur
as a consequence of depletion or a defect in the mitochondrial
antioxidant system (Camara et al., 2010b). The increase in ROS
production can contribute to a self-regenerating ROS production
facilitated by ROS-induced ROS release (Zorov et al., 2000; Brady
et al., 2006b; Stowe and Camara, 2009). This increase in oxidative
stress will result in further damage to mitochondria. A point is
reached where the scavenging system almost completely collapses
and emission of ROS is further perpetuated in a vicious cycle.
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The free radical NO that is released from the vascular
endothelium probably exerts an important role in regulating
mitochondrial respiration. NO and its derivatives have emerged
as significant players in the control of mitochondrial function and
dysfunction (Camara et al., 2010b). Some of the effects of RNS
include: (1) competitive inhibition of cytochrome oxidase (complex IV), (2) partial inactivation of complex I, (3) activation of
mPTP, and (4) stimulation of mitochondrial biogenesis (Camara
et al., 2010a).
The inhibition of complex I by S-nitrosation has surfaced
recently as an important mechanism in cardioprotection by IPC
due to the direct action of NO on mitochondria independent of its
effects on the soluble guanylate cyclase signaling pathway (Burwell
et al., 2009). In a way, the partial inhibitory effect of NO on complex
I is analogous to the protective effect afforded by amobarbital on
complex I (Aldakkak et al., 2008a). However, the effect of NO
−
to bind to complex I can also result in increased O2 and H2O2
−

NO
reacts with O2 to gen(Camara et al., 2010a). Furthermore,
erate the potent RNS product peroxynitrite (ONOO−; Figure 4).
The main source of NO in cardiac mitochondria likely arises
from the vascular endothelium, but there are other potential
cytosolic sources, such as nerve terminals or mitochondria. NO
has multiple targets in mitochondria including metalloproteins
containing Fe–S clusters that are known to be highly sensitive to
a direct oxidative modification by NO; other important targets
are the lipid thiols. Like O2− the role of NO and its products in
the cell is akin to a “double-edged” sword. NO can act both as
a vasodilatory and cardioprotective molecule and as a facilitator
of cellular injury. NO can act directly on mitochondria, independent of guanylate cyclase, to protect tissue/organs, or it can
provide protection by way of a NO -mediated signaling cascade.
But, the most important feature of NO in mitochondria is likely
the competitive, reversible inhibition of O2 binding at complex IV.
The NO inhibition of O2 binding is reversible as this depends on
the concentration of the two gases in the mitochondrion (Camara
et al., 2010b).
Although there is considerable support for the concept that
NO per se is cardioprotective, the exact mechanisms for this effect
remains to be unraveled. Under physiological conditions, when the
O2 concentration is low, NO may effectively act as a regulator of
the mitochondrial ETC to induce reversible inhibition of e− transfer. In this situation, NO generation during hypoxia may lower
mitochondrial respiration as an adaptation to lower O2 availability
(Harrois et al., 2009). In addition, inhibition of complex IV by
NO is thought to elicit cardioprotection by preserving the limited
supply of O2. NO , in limited amounts, may also provide protection against I/R injury in part by preserving cardiolipin (discussed
above under IMM), which is essential for complex IV function,
and to minimize cytochrome c release and other apoptotic factors
(Gorbunov et al., 1997; Osipov et al., 2006; Vlasova et al., 2006). Of
course, nitration of amino acid residues in the ETC complexes and
other proteins (VDAC, ANT), likely leads to altered enzyme function. Nitrosation of complex I on the other hand, has been shown
to protect against I/R injury (Nadtochiy et al., 2007). In a recent

study, Cheng et al. (2011) reported that NO caused a concentration-dependent biphasic inhibitory effect of the cardiac VDAC
that was incorporated into a planer lipid bilayer. The implications
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of these novel findings is that post-translational modification of
VDAC by NO and other nitrogen containing molecules may be
important in regulating the function of the channel, thereby preserving mitochondrial function and cell survival. Lastly, NO is
reported to decrease mCa2+ overload by binding to complex I and
this appears to be associated with a decrease in ∆Ψm (Solaini and
Harris, 2005; Burwell and Brookes, 2008). NO is a mediator of
preconditioning through several putative pathways (Camara et al.,
2010b). It is plausible that some of the protective effects of NO can
also be attributed to a coordinated series of responses by modest
levels of NO , which indirectly enhances mitochondrial function
by increasing local blood supply to enhance O2 and substrate delivery to mitochondria (Camara et al., 2010b).
At higher concentrations, NO appears to shift the balance from
cytoprotection toward damage and apoptosis. Increased mitochondrial NO may induce cell death by necrosis and apoptosis via
mPTP opening (Solaini and Harris, 2005). Indeed, as noted elsewhere, ONOO− is thought to be an important mediator of tissue
injury in myocardial ischemia-reperfusion (Camara et al., 2002).
The most damaging effects of NO activity on mitochondria are
attributed to an increased susceptibility of cardiolipin to ONOO−
(Chen et al., 2007). It is important to note that while NO mainly
reacts reversibly at complex IV, ONOO− is known to affect complexes I, II, and V by irreversible nitration of the tyrosine residues
(Duchen, 2004). Thus conditions leading to excess ONOO− will
promote enhanced mitochondrial lipid/protein damage, Ca2+
uptake and swelling, rupture or increased permeabilization of
OMM and cytochrome c release. ONOO− also can directly oxidize
glutathione (GSH; (Harrois et al., 2009).
The balance between physiologically relevant levels and pathological concentrations of NO is critical in the role of this gas
in mitochondrial function (Kim et al., 1999) and points out the
difficulty in maintaining a delicate balance between NO generation and ONOO− production during development of potential therapeutic approaches to target mitochondria. Given that
ONOO− is an intermediate formed from NO and O2− , inhibition of either O2− or NO generation will attenuate the levels
of ONOO− and minimize mitochondrial damage (Camara et al.,
2010b). For example, overexpression of MnSOD has been shown
to protect neuronal-like cells against NO -dependent cell injury,
tyrosine nitration, and lipid peroxidation. In addition, overexpression of nNOS initiates NO -dependent neuronal cell death,
which is alleviated in cells enriched in MnSOD (Radi et al., 2001).
However, the chemical reaction between NO and O2− is faster
than the reaction with MnSOD (Ferdinandy and Schulz, 2003)
and ONOO− mediated inactivation of the enzyme amplifies NO
and ONOO−-dependent mitochondrial oxidative stress (Radi
et al., 2001). It is reported that ONOO− can inhibit mitochondrial aconitase (Hausladen and Fridovich, 1994) and stimulate the
release of AIF and other apoptogenic factors from mitochondria,
which in turn leads to DNA fragmentation or increased cytochrome c peroxidase activity that can worsen the oxidative damage
of mitochondrial proteins and membranes (Szabo et al., 2007).
Overall, a targeted approach against excess ONOO− and NO
with allowance for “small” concentrations of NO as a signaling
mediator for cytoprotection may be an important initial strategy
to protect against cardiac cell injury from oxidative/nitrosative
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stress (Camara et al., 2010b). Indeed at low concentrations even
ONOO− has also been reported to be cardioprotective (Nossuli
et al., 1998).
Low levels of ONOO−, however, may actually provide protection (Camara et al., 2010b) through its decomposition products,
NO2 and NO3 (Szabo et al., 2007), by reacting with glutathione
to form S-nitrosoglutathione (Nossuli et al., 1998), and/or by
acting as an intermediate in preconditioning (Ferdinandy and
Schulz, 2003). The earliest evidence in favor of a protective effect
of ONOO− is its decomposition to other nitrogen compounds by
the Fe(III) porphyrin compounds in the carrageenan-induced paw
edema model (Szabo et al., 2007). Since then, other studies have
reported ONOO− furnishes protection against diabetes-associated
impairment of erectile dysfunction and I/R injury. In I/R injury
the cardioprotective effect were demonstrated by reduced infarct
size and improved contractile function (Ronson et al., 1999; Szabo
et al., 2007).
In cardiomyocytes, ONOO− protection may be mediated in part
by nitration of PKCε, which in turn activates mitoKATP channels
resulting in inhibition of mPTP opening. ONOO− conversion to
NO in the presence of hemoglobin, or decomposition of nitrite
in the presence of myoglobin nitrite reductase to form NO, may
all lead to protection by inhibiting complex IV or by activation
of mitoKATP, to block mPTP opening (Gladwin and Kim-Shapiro,
2008; Nediani et al., 2011). As noted above, NO can also inhibit
the ETC thus tending to preserve O2 gradients during ischemia and
to favor a more controlled resumption of respiration during reperfusion to minimize ROS production (Nediani et al., 2011). Clearly,
the mechanism of protection by nitrogen containing molecules,
such as nitrites, await further characterization, and the reproducibility of this effect in multiple animal models of I/R suggests nitrite
as a novel potential therapy for ischemic heart diseases (Nediani
et al., 2011).
Potential therapeutic value of mitochondrial ROS
scavenging

Under physiologic conditions, scavengers or antioxidants can
attenuate the toxic effects of ROS and RNS. This is because mitochondria are endowed with an elaborate and well-defined multileveled antioxidant defense system of enzymes and non-enzymes
to quench mitochondrial O2− . The scavenging system includes the
matrix MnSOD and glutathione (GSH; Figure 4) and thioredoxin
(TRXSH2) systems, cytochrome c, peroxidase, catalase, and others.
A detailed review of ROS scavengers, which is beyond the scope
of this review, has been discussed in recent comprehensive review
articles by two of the authors (Stowe and Camara, 2009; Camara
et al., 2010b).
The association of increased ROS generation in various pathological conditions has made development of the ideal antioxidant
therapy to target the mitochondrion an important goal (Camara
et al., 2010b). Recent evidence suggests that targeting O2− emission during I/R requires adoption of alternative approaches, i.e.,
focusing on the O2− generation that occurs during ischemia as well
as the O2− emission during reperfusion (Camara et al., 2010b).
O2− generation during ischemia sets the stage for an increase in
O2− emission during reperfusion as a mechanism of cellular injury
(Chen et al., 2007, 2008; Aldakkak et al., 2008a). As noted before,
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blockade of complex I and III with amobarbital and antimycin A,
respectively, can protect mitochondria against ischemic damage
(Chen et al., 2010). Clinically, this is a relevant area of research
because patients with active myocardial ischemia could theoretically receive pharmacologic therapies that target the spatial and
temporal aspects of ROS production. Pharmaceutical agents that
provide ROS scavenging systems are most effective if they address
the problem at its source, in this case within the IMM (Hoye et al.,
2008). Overall, a better understanding of the sources and direction of O2− generation from the mitochondrion is crucial to an
understanding of the potential of particular antioxidants used to
mitigate oxidative stress and cellular damage. However, effective
delivery of these antioxidants into the cytosol or matrix as a therapy
remains elusive and problematic. Attempts to address these physical limitations are being pursued by reformulations of different
therapeutic antioxidants based on the much larger ∆Ψm than cell
membrane potential.
Because MnSOD is located primarily in the matrix (Figure 4), it
plays an essential role in protecting against oxidative stress, and is
therefore a critical component of normal development and survival.
Its only known function is to detoxify O2− to H2O2. MnSOD is a
nuclear-encoded protein that is transported to the mitochondria via
a targeting sequence through the import machinery. A number of
studies have shown better cell survival under oxidative stress, e.g.,
lipopolysaccharide treatment, by increasing the level of MnSOD
(Czaja et al., 1994; Rogers et al., 2001). In SOD2+/− mice, brain
infarct size is greater than wild type after focal cerebral ischemia.
Accordingly, overexpression of MnSOD results in neuroprotection
(Duckles et al., 2006).
Mitochondrial MnSOD mimetics (non-protein) have been
developed to allow uptake into the mitochondrion to scavenge ROS.
The mitochondrial superoxide dismutase mimetics MnTBAP and
MnTE-2-Py5+ are permeable to the IMM and are capable of scavenging O2− and ONOO− (Saba et al., 2007). MnTBAP was shown to
improve survival in MnSOD knock out mice (Benov et al., 1998) and
to decrease mitochondrial ROS production (Camara et al., 2004).
Another cell-permeable MnSOD mimetic, Mn(III)tetrakis[(1methyl-4-pyridyl)-porphyrin] (MnTMPyP), has both MnSOD and
catalase effects (Wang et al., 2004). Indeed, we observed that when
MnTPyP was given before prolonged cold ischemia, it protected the
isolated heart from ROS damage during I/R (Camara et al., 2007).
The variant form of the porphyrin MnTE-2-Py5+, MnTnHex-2-Py5+,
given 24 h before ischemia, preserved endogenous MnSOD and
F0/F1 ATP synthase activities, with a concomitant increase in renal
functional recovery. This action was unlike the classic MnSOD
mimetics (Saba et al., 2007). However, it is unfortunate to note that
attempts to incorporate these antioxidants in human cardiovascular
preservation techniques remain either untested or are largely disappointing (O’Connor and Gutterman, 2010). One would hope in
time, and with rigorous testing and reformulations, the potential
beneficial role of synthetic scavengers could lead to novel and useful
mitochondriotropic antioxidants (Camara et al., 2010b).
In general, cellular antioxidant defenses depend on the reduction potential of the electron carriers and the reducing capacity
of linked redox couples in the matrix [NADH/NAD+ and FADH2/
FAD] and cytoplasm (Stowe and Camara, 2009; Camara et al.,
2010b). The balance between oxidized and reduced species, i.e.,
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GSH/GSSG and pyridine nucleotides (NADH/NAD, NAD(P)H/
NADP), determine the cellular redox status. Oxidative stress and
redox status are widely considered as major facets of mitochondria-related diseases/abnormalities. In fact, one defense against
I/R-induced ROS accumulation and damage may involve preservation of the NAD(P)H pool (Camara et al., 2010b). An adequate
NAD(P)H/NAD ratio, maintained through an NADH kinase and
transhydrogenase (Hanukoglu and Rapoport, 1995; Outten and
Culotta, 2003)-dependent mechanism, preserves the mitochondrial
NAD(P)H pool required to maintain the redox status necessary
for effective scavenging. Thus the redox homeostasis in mitochondria is regulated by the coordinated activity of various antioxidant
mechanisms including the GSH, thioredoxin (TRX; Camara et al.,
2010b), and other redox systems. Therefore, these thiol-reducing
agents are critically involved in defense against large increases in
O2− emission (Sen, 1998; Ueda et al., 1998; Lin and Beal, 2006;
Stowe and Camara, 2009).
GSH is a small molecule with a thiol (-SH) residue of cysteine as
its active site. Under conditions of oxidative stress, large amounts
of GSH are rapidly oxidized to GSSG. The enzyme glutathione
reductase (GR) uses NAD(P)H/NADH as its source of e− to regenerate GSH. Hence an increased concentration of NAD(P)H/NADH
relative to NADP+/NAD+ promotes the production of GSH via GR
(Figure 4). GSH protects mitochondria from extra-mitochondrial
ROS and detoxifies O2− in a non-enzymatic fashion. Mitochondria
appear to be most susceptible to damage during a GSH-depleted
state (Stowe and Camara, 2009; Camara et al., 2010b). Inhibition
of GSH transport results in depletion of mitochondrial GSH and
increased oxidative damage (Aon et al., 2007) and subsequent cellular injury. In addition to protection against ROS, GSH is an ideal
scavenger of HNE and other lipid peroxides (Calabrese et al., 2005).
Mitochondrial thioredoxin reductase-2 (TrxR-2) is present in
large concentrations in the brain, heart, and liver (Rybnikova et al.,
2000). TRX is reduced by TrxR-2, which utilizes the mitochondrial
NADH/NAD redox state similar to GR as a source of reducing
equivalents. TRX protected against H2O2-induced cytotoxicity,
improved post-ischemic ventricular recovery, and reduced infarct
size when compared to hearts from wild type mice (Ebrahimian
and Touyz, 2008; Ebrahimian et al., 2008). The TRX system has also
been shown to have a potential therapeutic value against cardiac
hypertrophy and cardiac failure (Stowe and Camara, 2009; Camara
et al., 2010b).
The contribution to scavenging potential of mitochondria by
these redox proteins is therefore dependent on normal mitochondrial bioenergetic function and the availability of reducing equivalents. Thus, maintaining a large pool of reductants like GSH and
TRX requires mitochondria to regenerate the reduced state via the
NADH/NAD+ redox pair after detoxifying the ROS. Hence, supplying exogenous GSH or TRX-2 may be protective, but only if there
are also sufficient reducing equivalents.
Catalase is present in the cardiac cell mitochondrial matrix in
extremely small amounts (Andreyev et al., 2005). Catalase protects mitochondria against intra- and extra-mitochondrial generated H2O2 (Andreyev et al., 2005). GPx, ubiquitously expressed
in mammalian tissues and present in the mitochondrial matrix,
seems to be the dominant H2O2 detoxifying agent in the heart.
Catalase or GPx coupled to GR converts H2O2 to H2O (Fruehauf and
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Meyskens, 2007) to mitigate oxidative stress. Overexpression of
GPx improves left ventricular pressure in mice after myocardial
infarction (Laskowski and Russell, 2008). Recent studies have also
shown that targeting catalase to the mitochondria can reduce cardiac pathology (e.g., cardiomyopathy with age) consistent with the
effect of accumulated endogenous ROS that may decrease heart
functional capacity with aging (Treuting et al., 2008).
Lastly, cytochrome c, which is one of the mediators of apoptosis, can accept or donate an e− depending on the redox state of its
heme (Fe). In this way it is also a scavenger of O2− (Camara et al.,
2010b). The reduced cytochrome c is reinstituted by donating its
e− to complex IV. In I/R injury, loss of cytochrome c through mPTP
or OMM permeabilization, as a result of oxidative damage to cardiolipin and membrane proteins, inhibits or slows down respiration,
which leads to increased e− leak (Zhao et al., 2003; Li et al., 2006);
the outcome is a vicious cycle of more O2− production and more cell
damage. In the cytochrome c deficient Keilin–Hartree heart muscle
model, Zhao et al. (2003) showed that e− transfer was impaired and
O2− generation was significantly greater in the mutant than in the
wild type mouse. Reconstituting cytochrome c in the cytochrome
c deficient hearts resulted in less O2− accumulation. Therefore, an
adequate concentration of cytochrome c in the ETC process is necessary to maintain ROS at physiological levels (Zhao et al., 2003).
Hence, maintaining the structural and functional integrity of the
IMM and cytochrome c levels could represent a potential strategy
for mitigating mitochondria dysfunction (Camara et al., 2010b)
(Figure 3).
Thus it can be summarized here that under pathological conditions a good understanding of the balance between the O2− producing side and its scavenging side is crucial for an effective therapy
(Camara et al., 2010b). In ischemia the excess O2− appear to be
confined to the production side and less to the detoxifying side. This
is evident by the apparent intactness of the scavenging capability
of GPx and MnSOD in isolated mitochondria during the ischemic
insult (Starke et al., 1997; Jin et al., 2005). In the failing heart,
on the other hand, increase ROS production is attributed in part
to decreased expression of MnSOD and catalase (Laskowski and
Russell, 2008). With these findings, the importance of decreasing
oxidant stress in the ischemic and failing heart prior to reaching
a critical mass that leads to irreparable damage is evident. Hence
targeting the ETC to attenuate e− transfer and consequently to
decrease the e− leak may represent a better strategy than attempting to change the matrix antioxidant capacity during ischemia
(Camara et al., 2010b).
Maintaining intra-mitochondrial and intra-organellar
interactions as a potential therapeutic strategy

It is believed that in certain cell types, mitochondria are organized in a reticular system of interconnected organelles, whereas in
cardiac cells they are thought to exist as individual units capable of
undergoing dynamic fusion and fission (Dorn and Scorrano, 2010).
These are processes that are regulated by fusion and fission proteins
(Archer et al., 2008; Camara et al., 2010a), and they play a major
role in regulating mitochondrial function and cellular metabolism.
However, the occurrence of mitochondrial fusion and fission in
the healthy adult heart is presently unclear, as these myocytes do
not normally divide. Furthermore, Collins et al. (2002), Aon et al.
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(2003, 2006b), and a several other investigators (Zorov et al., 2000,
2004; Vendelin et al., 2005), have reported that fusion and fission
are neither required for normal mitochondrial function in cardiomyocytes, nor in all cell types. Consistent with these observations,
Beraud et al. (2009) in an elaborate study, examined quantitatively
the structural organization of mitochondrial dynamics and movement in two different types of heart cells, i.e., adult cardiomyocytes
and non-beating HL-1 (NB HL-1) cells, and reported that NB HL-1
cells, but not the adult cardiomyocytes, showed fusion and fission.
The dynamic fission and fusion in the NB HL-1 cells were observed
only in dividing cells, which undergo rapid fusion–fission with
formation of reticular networks. The observed differences between
adult cardiomyocytes and NB HL-1 cells, according to the authors,
are related to the specific structural organization of the cells, e.g.,
a variance in the mitochondria-cytoskeletal architecture (Beraud
et al., 2009). From their findings, the authors (Beraud et al., 2009)
contended that fusion and fission are demonstrated only in cultured
cells of higher organisms or in yeast when these cells are actively
dividing. They also argued that if mitochondria were fused in the
cell, isolation of mitochondria should disrupt all mitochondrial
membranes and release TCA cycle intermediates and render the
mitochondrion unresponsive to TCA cycle linked susbtrates, e.g.,
pyruvate and glutamate (Beraud et al., 2009).
Nevertheless, fission and fusion have been implicated in a variety
of biological processes, physiological, e.g., embryonic and neonatal
development and metabolism, and pathological, e.g., I/R injury,
heart failure, “diabetic” heart, vascular dysfunction, and apoptosis
(Ong and Hausenloy, 2010; Williamson et al., 2010). Therefore,
fusion and fission may be important in the etiology and/or propagation of mitochondrial dysfunction and ultimately cellular disorder,
in some vascular cell types, such as endothelial cells. For example,
fission might reduce propagation of mitochondrial ROS leading
to less lipid peroxidation and loss of ∆Ψm, whereas fusion might
facilitate spread of ROS and lead to mitochondrial destruction.
Fission can also prevent cell death induced by Ca2+-dependent
apoptotic stimuli that require mitochondria to amplify the lethal
signals of this second messenger (Dorn and Scorrano, 2010).
However, abnormal fission results in fragmented and bioenergetically impaired mitochondria. Fission also leads to destabilization
of mitochondria while fusion may promote stable mitochondrial
architecture and function. Yu et al. (2008) reported, for the first
time, that maintenance of the tubular mitochondrial network by
inhibiting mitochondrial fission in a sustained hyperglycemic condition normalized cellular ROS levels and thwarted mPTP opening
and subsequent cell death. Therefore, an understanding of this
complex dynamic interaction between mitochondria, and between
mitochondria and other organelles, is central to understanding
the underlying causes of cellular dysfunction. It may also provide
a potential for discovering novel therapeutic strategies for treating
cardiovascular diseases (Ong and Hausenloy, 2010) using alternative protective mechanisms against oxidative stress.
Mitochondria can fuse with each other with the support of
the cytoskeleton. Changes in the cytoskeletal architecture have
recently been documented in patients with end-stage dilated and
ischemic cardiomyopathies and, as such, may represent a common
path for contractile dysfunction in the failing heart (Camara et al.,
2010a). Mitochondria are also capable of fragmenting into more
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individual mitochondria and this may be beneficial or harmful
to the cell. For instance, mitochondria fission or failure of fusion
appears to engage apoptotic mechanisms leading to cell degeneration (Duchen, 2004). Oxidative stress is one of the major triggers of impaired mitochondrial dynamics. Substantial evidence
indicates that mitochondrial fission occurs as a result of oxidative
stress, which leads to loss of ∆Ψm and consequently to impaired
mitochondrial function and increased cell vulnerability. For example, acute exposure of myocytes to H2O2 leads to p53-dependent
mitochondrial network fragmentation and the extent of the mitochondrial fragmentation (Li et al., 2010) correlates with a decrease
in ∆Ψm (Camara et al., 2010b).
Indeed, in normal cells ∆Ψm is required for fusion. Specific
fission and fusion proteins regulate this dynamic relationship by
maintaining the IMM and by controlling cytochrome c release
(Camara et al., 2010b). In cells derived from disease states, the
compromise in ∆Ψm is a consequence of defects in ETC complexes (McBride et al., 2006; Taguchi et al., 2007). This dynamic
disintegration is observed in numerous mitochondrial associated
cytopathies, including neurodegenerative diseases (Kwong et al.,
2007), pulmonary artery hypertension (Archer et al., 2008), and
I/R injury (Aon et al., 2006a; Brady et al., 2006a). In pulmonary
artery hypertension a decrease in mitofusin proteins contributes to disruption of mitochondrial fusion (Archer et al., 2008).
Therefore, maintaining mitochondrial fusion by expression of
fusion proteins, while minimizing the levels of fission proteins
(Wang et al., 2009), could represent a novel therapeutic approach
to improving cell survival during oxidative and nitrosative stress.
In many diseases, in which a less polarized ∆Ψm may contribute
to mitochondrial instability, a strategy to maintain integrity of
the ETC with normal e− flux is a therapeutic option (Camara
et al., 2010b).
Mitochondria also have anatomical and functional connectivity
with other organelles such as the nucleus and the SR. These dynamic
functional and structural interconnections are important for the
normal coordination of cellular function. It is therefore anticipated
that derangement of this dynamic link could be involved in pathologic states associated with cellular dysfunction. In some cell types,
e.g., myocytes, mitochondria lie in very close apposition to the SR,
and so are exposed to microdomains of high cytosolic [Ca2+] following local Ca2+ release from the SR. Evidence has emerged that
there is a preferential coupling of Ca2+ transport from SR directly to
mitochondria (Sharma et al., 2000), thereby providing a means for
coupling cardiac muscle excitation to oxidative energy production,
possibly through activation of Ca2+ sensitive mitochondrial dehydrogenases (Csordas et al., 2001; Hajnoczky and Csordas, 2010).
Mitochondria–SR communication is therefore a crucial component
in the normal function of mitochondria within the cell. The anatomical proximity between mitochondria and ER conversely creates
a local mitochondrial [ATP] within the microdomain required for
SR Ca2+ regulation (Duchen, 2004; Szabadkai and Duchen, 2008;
Figure 2). This dynamic relationship highlights the importance of
Ca2+ signaling between the two compartments. For example, the
low conductance form of the Ca2+-induced mPTP opening leads to
Ca2+ extrusion from mitochondria; this may serve as an amplification loop for Ca2+-induced Ca2+-release from the ER or SR stores
(Pereira et al., 2009).
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In the heart the inter-fibrillar mitochondria are closely intertwined with the SR to provide functional communication between
the local ATP and the site for contraction (Dalen, 1989). Therefore,
this proximity of mitochondria to Ca2+ release sites has functional
consequences for intracellular Ca2+ signaling, capacitative Ca2+
influx, and cellular function (Duchen, 2004) and dysfunction
(Camara et al., 2010b). Mitochondrial Ca2+ dynamics as well as
emission of ROS are thus two key important events during the
course of cellular injury and cell death. It has been proposed that
these interactions are modulated in part by locally generated mitochondrial ROS, which is believed to act as the trigger to regulate
the Ca2+ flux between the organelles (Waypa et al., 2002; Walsh
et al., 2009) (Figure 2). A strategy of combined protection of mitochondria-SR dynamic anatomic and functional relationship may
represent an innovative therapeutic approach to enhance organ
viability (Du et al., 2008).
Examples of potential therapeutic compounds to protect
mitochondrial function

Given the marked importance of mitochondrial events during the
initial critical phases of apoptosis, or in the propagation of many
disease processes, the appropriate design of mitochondriotropic
drugs is crucial in developing promising, novel strategies to mitigate
cell injury and to prevent cell death. Because of the importance
of this organelle in disease processes, either secondary or primary, a new field has emerged in the clinical realm that recognizes
“Mitochondrial Medicine.” This is a new and rapidly developing
medical research field. In recent years, the scope of the Society of
Mitochondrial Medicine has expanded to pay increased attention
to promote research and education for the diagnosis, treatment,
and cure of mitochondrial disorders.
Mitochondria are ideal targets for therapeutic modification
because they are key producers of ATP and ROS production,
whereby an imbalance of the two factors can lead to apoptosis. As
a first step in designing a mitochondria-specific therapy, it is foremost important to develop a drug that can access the matrix. One
general solution is to utilize the large ∆Ψm and to attach a molecule,
for example one with antioxidant properties, onto a lipoid vehicle
that can penetrate membranes (Hoye et al., 2008). With a ∆Ψm of
−180 mV under state 4 conditions, mitochondria-targeted drugs
are preferentially taken up into the mitochondrion, with little or
no accumulation in the cytosol (Camara et al., 2010b).
To achieve this goal, numerous approaches have been attempted.
For example, the lipophilic agent TPP+, mentioned earlier, has been
used to increase the incorporation of antioxidants and other therapeutic impermeants into mitochondria. The appended positively
charged phosphonium moiety induces about a 1000-fold uptake of
these compounds into the matrix over the cytoplasm. Indeed antioxidants that accumulate within the matrix provide better protection from oxidative injury than untargeted antioxidants (Milagros
Rocha and Victor, 2007). Examples include mitochondria-targeted
ubiquinone (MitoQ), mitoTEMPO, and idebenone, currently
under study for their possible use as therapies to decrease oxidative damage in human pathological conditions (Maroz et al., 2009).
These drugs accumulate in the mitochondria and could enhance
ETC function, scavenge ROS, and prevent oxidation of cardiolipin, all of which may result in better functioning of m
 itochondria
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(Schapira, 2006; Pope et al., 2008). CoQ10 is a natural antioxidant
and a highly mobile e− carrier between complexes I and II to III. It
is redox active and has been effective in reducing oxidative stress.
It may provide some protection for patients with mitochondrial
cardiomyopathies (Sokol and Treem, 1999).
Another mitochondrial-targeted antioxidant, the cationic
SOD2 mimetic MnTBAP, can accumulate in cardiac mitochondria
after systemic injection (Spasojevic et al., 2007). We showed that
MnTBAP reversed the protection provided by the putative mitoKCa
channel agonist NS 1619 (Stowe et al., 2006) and by IPC (Kevin
et al., 2003). This demonstrates the fine line between scavenging
harmful ROS and the ROS that are essential for signaling purposes.
The mitochondrial-targeted scavenger mitoTEMPO decreased O2−
and attenuated AII-induced hypertension, whereas when a similar
dose of the non-targeted TEMPOL was given it was ineffective. The
effect of mitoTEMPO was mimicked by overexpression of MnSOD
(Dikalova et al., 2010). In an unrelated study, it was reported that
SOD1 and mitoTEMPO prevented translocation of Bax to mitochondria and preserved mitochondrial integrity during simulated
oxidative stress in tubular epithelial cells (Liang et al., 2010).
Metformin, an anti-diabetic drug also accumulates in the matrix
of energized mitochondria due to its positive charge (Owen et al.,
2000). Metformin has a broad spectrum of effects that include fat
breakdown and an increase in glucose transport and utilization
(Zmijewski et al., 2008). Metformin has also been shown to protect
against I/R injury (Calvert et al., 2008), possibly through the direct
effects of the drug on complex I (Brunmair et al., 2004; Zmijewski
et al., 2008), another action analogous to the action of amobarbital
on mitochondria (Aldakkak et al., 2008a). Recent evidence suggests
that metformin also can protect against oxidative stress. Metformin,
via AMP-activated protein kinase, was reported to upregulate the
expression/activity of thioredoxin, which, e.g., can attenuate the
ROS generated by an enhanced FA load (Nediani et al., 2011). In
the murine model of heart failure caused by I/R injury, metformin
was effective in decreasing left ventricular dysfunction. This could
make metformin a suitable mitochondria-directed therapy for protection against I/R injury and other cardiac vascular complications,
particularly in the non-diabetic patient with heart failure (Nediani
et al., 2011).
Another drug that also directly targets the mitochondrion is
resveratrol (Sareen et al., 2006). Mitochondria represent a powerful target for resveratrol in the nervous system (Raval et al., 2008).
Resveratrol is a polyphenolic compound derived from some grapes
and roots; it is a natural antioxidant. It has been shown to reduce
oxidative stress developed during reperfusion of the ischemic heart;
it may also be in part effective against hypertension, cardiomyopathy, and heart failure (Das et al., 2010). Resveratrol has been
shown to induce NO synthesis in the setting of ischemic reperfused
heart, brain, and kidney, where it may lower the oxidative damage
(Das et al., 2010). It has also been demonstrated that resveratrol
can improve mitochondrial function and provide cardioprotection
by stimulating the sirtuin 1 (SIRT1)-dependent deacetylation of
the transcriptional co-activator peroxisome proliferator-activated
receptor-γ co-activator 1α (PGC-1α) in a NAD+-dependent manner. Because sirtuin depends on cellular NAD+ availability, mitochondrial regulation of NAD+ levels may contribute to an increase
in sirtuin mediated PGC-1α deacetylation. Activation of PGC-1α
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co-activates nuclear transcription factors involved in OxPhos,
increases mitochondrial biogenesis and enhances O2− detoxification enzymes MnSOD and catalase (Das et al., 2010; Fulda et al.,
2010), all of which contribute to protection. At high concentrations resveratrol has been shown to act as a pro-oxidant (Raval
et al., 2008); it could also lead to inhibition of mitochondrial ATP
synthesis by binding to F1-ATPase, or by triggering mPTP opening, which would eventually contribute to cell injury. This suggests
that the therapeutic role of resveratrol, as with other drugs, may be
dependent on the concentration of the drug (Szende et al., 2000;
Morin et al., 2003a).
There has recently emerged a novel class of cell-permeable antioxidant peptides that are selectively partitioned into the mitochondrion independent of the ∆Ψm. These series of peptides, known as
Szeto–Schiller (SS)-peptides can selectively target the IMM. For
example, SS-31, which scavenges matrix H2O2 and ONOO−, reduced
cytochrome c release and minimized mitochondrial swelling; its
efficacy has been demonstrated in vivo by its effect to reduce cardiac
and brain I/R injury in animal models (Cho et al., 2007; Thomas
et al., 2007; Szeto, 2008a,b).
Other novel pharmacological agents may effect organ protection by optimizing substrate metabolism (discussed later) or by
maintaining or improving oxidative capacity. However, it is clear
that the subject of mitochondrial pharmacology is vast and the discussion presented here represents only a sampling of what has been
uncovered to date. Nonetheless, the notion to use mitochondrialtargeted therapeutics as an alternative approach is becoming an
increasingly attractive strategy for treating cardiovascular diseases.
One can predict that there will be whole classes of these so-called
“mitochondriotropic drugs” under development in the near future.
Potential therapeutic implications directed toward
mitochondrial Ca2+ handling

Mitochondrial Ca2+ handling plays a key physiological and pathophysiological role in the control of cellular function and dysfunction. Mitochondrial Ca2+ overload is a deleterious consequence
of cardiac I/R injury and so mitochondrial Ca2+ handling is an
important target for potential therapy (Camara et al., 2010b). As
noted previously, the primary source of mCa2+ is external to the
cell or from Ca2+ stored in the SR, following an increase in cytosolic
Ca2+ uptake. Although modest increases in m[Ca2+] enhance enzymatic activity and subsequently OxPhos, massive mCa2+ loading
can disable ATP synthesis. Under simulated or true I/R conditions
the excess mCa2+ may contribute to mPTP opening and destabilization of cellular ionic homeostasis, and eventually to cell death
by necrosis or apoptosis. However, the targeting of mCa2+ dynamics (uptake and release) for therapeutic purpose creates a difficult
challenge that could impede the way forward in this area. These
impediments include the structural identification of the CaU, NCE,
NHE and a sodium-independent Ca2+ exchanger (NICE), and the
myriad of other purported molecular structures that regulate the
dynamic Ca2+ flux between the SR and mitochondria (see above).
Suffice it to say, however, that attempts have been being undertaken to target mCa2+ in order to mitigate oxidative damage or
I/R injury. Therapeutic approaches to reduce mCa2+ uptake leading to protection may involve direct targeting of the CaU or the
mitochondrial exchangers that regulate m[Ca2+], or may involve
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indirect approaches that reduce Ca2+ release in the mitochondria-SR
microdomain. For example, attenuation of mCa2+ overload and the
subsequent reduction in the sensitivity of the mPTP opening has
been attributed in part to inhibition of NHE or the CaU. Blocking
NHE preserved ATP levels during cardiac I/R by improving state
3 respiration (Javadov et al., 2008) and preventing mitochondrial
Ca2+ overload (Camara et al., 2010b). In a recent study we also
reported that activation or inhibition of NHE might act through
mitochondria as shown by changes in redox state, ROS generation,
and mCa2+ levels. We concluded from this study that the protection
afforded by NHE inhibition may be due at least in part to inhibited
mNHE, as well as sarcolemmal NHE. This notion is consistent
with the observation that cariporide blocked matrix acidification
and ATP depletion during simulated ischemia in cardiac myocytes
(Ruiz-Meana et al., 2003). Under these conditions, one would
expect a decrease in matrix pH with concomitant mitochondrial
depolarization leading to diminished Ca2+ uptake.
The mNCE is another putative mitochondrial Ca2+ transporter,
which is likely functionally similar to the sarcolemmal NCE, and
it is sensitive to cations and a variety of pharmacological agents
such as diltiazem and more specifically CGP37157 (Rizzuto et al.,
2009). Like the sarcolemmal NCE, the mNCE can operate in both
directions depending on the trans-membrane cation concentrations. During metabolic inhibition an increase in mCa2+ levels was
observed despite a reduced ∆Ψm, which would limit uptake through
the CaU (Hoppe, 2010). Indeed, it was reported that the rise in
mCa2+ observed during metabolic inhibition was minimized by
CGP37157. This mode of action may be particularly significant in
diseased states with elevation of cytosolic Ca2+ and Na2+ levels during heart failure (Hoppe, 2010). In addition, strategies to enhance
extrusion of mCa2+ through the exchanger could lead to diminished
mCa2+ load and reduce mitochondrial damage. This would make
the targeting of mNCE a potential therapeutic target for mitigating
Ca2+ overload during ischemia. However, direct targeting of these
drugs to mitochondria with greater efficacy than on sarcolemmal
exchangers remains elusive in so far as the molecular identity of
the exchanger/transporters remains obscure.
The CaU, due to its close anatomical and physiological proximity to the SR RyR, is implicated in both normal cellular function
and injury. Indeed, targeting the CaU in the local domain has been
shown to mediate protection against I/R injury in various models. It
has been shown to mediate IPC and to be directly involved in protection. Studies have shown that blocking the CaU with ruthenium
red (RR) or RU360 prior to ischemia decreased the incidence of
ventricular fibrillation (Brown and O’Rourke, 2010). We reported
in preliminary studies that RR improved function and reduced
mCa2+ load following I/R. Interestingly, we also observed in preliminary studies that RR significantly reduced the worsening of mCa2+
overload that was instituted by the perfusion of hearts with pH 8
buffer (Aldakkak et al., 2008c), a condition that would maximally
stimulate NHE and lead to increased cytosolic Ca2+ secondary to
activation of NCE. However, as noted by Brown and O’Rourke
(2010) in a recent review, it is difficult to draw conclusions on
the effects of blocking the CaU due to the confounding effects of
the ruthenium compounds on cellular Ca2+ fluxes, for example,
blocking SR Ca2+ release. Even the more specific RU360 is trapped
in controversy related to its membrane permeability. Until then,
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it is opined that future research with novel compounds that lack
these pleiotropic/permeability issues will provide better insights
into the role of CaU in cardioprotection.
SR stress results from a perturbation of SR homeostasis and
has been implicated in cardiac contractile dysfunction associated
with I/R and heart failure as a result of SR-induced intracellular [Ca2+] changes. Evidence suggests that IP3R-mediated release
of Ca2+ from the SR appears to be a key-sensitizing step in various apoptotic processes (Rizzuto et al., 2009). In early apoptosis,
Ca2+ released from the SR activates mPTP; with the subsequent
release of cytochrome c, this leads to an unrestrained increase in
the local cytosolic [Ca2+] (Romagnoli et al., 2007). This might
provide a direct mechanism for more matrix Ca2+ uptake. Ca2+
released via the IP3R is imported across the OMM through the
VDAC (Rizzuto et al., 2009). Overexpression of VADC enhances
mCa2+ uptake (Rizzuto et al., 2009) and this could offset the balance of mCa2+. All together, it is conceivable that interrupting the
interaction between mitochondria and SR could mitigate (or promote) mitochondrial-mediated cellular damage. Thus targeting
the dynamic Ca2+ flux within the microdomain, pharmacologically
or by genetic manipulations, could provide potential therapeutic
alternatives for reducing mCa2+ overload. Indeed, inhibition of SR
Ca2+ release kinetics was proposed to reduce mCa2+ uptake and prevent collapse of ∆Ψm or the release of cytochrome c (Rizzuto et al.,
2009). Akt phosphorylation of the receptor inhibits Ca2+ flux from
the SR to mitochondria (Szado et al., 2008) and thereby inhibits
apoptosis. Mao et al. (2008) in an elaborate study reported that the
compound darbepoetin alfa, via activation of Akt, improved cardiac
function and reduced cardiomyocyte apoptosis in a rabbit model
of autoimmune cardiomyopathy. Therefore intrinsic activation of
the Akt could be a potential therapeutic strategy in attenuating the
transfer of Ca2+ during SR-mitochondrial stress and changes in Ca2+
levels within the microdomain. It has been suggested recently that
mitochondria-SR crosstalk may play a greater role than previously
suspected in cardiac hypertrophy and the progression to heart failure. It is possible that in heart failure therapeutic manipulations
involving an increase sarcoplasmic reticulum Ca2+ ATPase (SERCA),
or impaired function of its endogenous inhibitor phospholamban,
could reduce the Ca2+ transient (Dorn and Scorrano, 2010) and
reduce m[Ca2+] by which to improve OxPhos with adequate ATP
production.
The mitochondrial K channels (ATP-sensitive or Ca2+ activated)
have been shown to have potential cardioprotective roles. The opening of mitoKATP or mitoKCa channels has been shown to be beneficial
for cell survival under certain stress conditions, including I/R and
heart failure (Ruiz-Meana et al., 2010). Opening of mitoKCa channels appear to protect hearts against infarction (Xu et al., 2002;
Stowe et al., 2006) and similarly, activation of the mitoKATP has
provided protection against I/R injury (Camara et al., 2010a). The
precise mechanism for this protection has yet to be fully elucidated. However, it is postulated that the opening of these channels
produces both an increase in mitochondrial volume and a certain
degree of uncoupling (mild depolarization) that reduces mCa2+
overload (Ruiz-Meana et al., 2010) and protects against apoptosis/
necrosis. We reported that activation of the mitoKCa channel with
NS 1619 resulted in cardioprotection from I/R injury and that this
was associated with reduced mCa2+ loading, better preservation
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of the redox state, and improved functional return (Stowe et al.,
2006). The activation of mitoKATP channels has also been proposed
to mitigate mCa2+ loading as a mechanism of protection against
I/R injury (Brown and O’Rourke, 2010).

Part 2
Mitochondrial dysfunction in endothelial cells, heart
failure, and I/R injury

Given the fundamental function of mitochondria in cellular
bioenergetics and oxidative stress, we have stressed that dysfunction within this organelle underlies the pathologic mechanisms
of many diseases. In this section, a brief discussion of the role of
mitochondria in vascular diseases, heart failure, and I/R injury will
be presented. Potential therapeutic approaches that are targeted to
mitochondria by which to mitigate cardiovascular damage also will
be discussed. When mitochondrial ATP production is impaired
tissues that rely heavily on high levels of ATP, such as the heart,
skeletal muscle, and brain, are most affected. Depletion of ATP can
lead, for example, to dissipation of intracellular ionic homeostasis, cell swelling, and subsequent cell death by necrosis. In heart
failure, defects have been purported to occur in ETC complexes
or in components of the OxPhos machinery. These alterations
are manifested frequently as cardiomyopathy (Rosca et al., 2008).
Concomitant with impaired ETC function and OxPhos, increased
O2− generation and mCa2+ overload occur and lead to a “vicious
perpetual cycle” of mitochondrial damage and dysfunction (Loeb
et al., 2005); ultimately mitochondrial functional decline will lead
to cell damage and organ failure.
Mitochondrial DNA is most susceptible to mutations because
of its lack of histones and a limited repair mechanism. Increased
oxidative stress leads to genetic mutations. Indeed, diseases related
to mtDNA defects appear to be more prominent in brain and in
skeletal and cardiac muscles where defects accumulate more extensively than in rapidly dividing cells (Muravchick and Levy, 2006).
It has been reported that in heart failure mtDNA damage leads to
dysfunction and loss of mitochondrial mass (Murray et al., 2007).
Mitochondrial related diseases have been discussed extensively in
the literature (Duchen, 2004) and in our recent comprehensive
review (Camara et al., 2010b).
Treatments targeted to endothelial and vascular cell
mitochondrial dysfunction

Endothelial cells play a major role in vascular diseases and so their
mitochondria are crucial in both the etiology and in the amelioration of the disease process. A primary role of the vasculature is in
facilitating the delivery of O2 and energetic substrates for powering the high metabolic demands of the cardiomyocytes; endothelial cells are also critical in the development and manifestation
of several types of cardiovascular disease that develop when the
vasculature becomes damaged (Pipinos et al., 2006). Damage to
endothelial cells can lead to atherosclerosis and to vascular complications associated with diabetes and other peripheral artery diseases. The manifestations of peripheral artery diseases are presumed
to be due to reduced blood flow and vessel compliance. However,
an increasing number of reports have implicated suboptimal bioenergetic function from impaired endothelial cell mitochondria as
an additional etiologic factor (Pipinos et al., 2006). The defective
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 itochondrial function in these vascular disorders may be analom
gous to mitochondrial associated myopathies with increased deleterious ROS production (Pipinos et al., 2006).
Under normal conditions, endothelial-derived NO may be able
to modulate cardiac contractility, heart rate, coronary flow, and
myocardial energetics. In pathological situations this role may be
extended to regulation of cardiomyocyte metabolism and determination of cell survival. Unlike the cardiomyocyte, the endothelial
cell is dependent more on glycolytic ATP production (cytosolic substrate level phosphorylation) and less on mitochondrial OxPhos.
Endothelial cells have far less mitochondrial density than cardiomyocytes (5 vs. 40% cell volume, respectively). Consequently, mitochondrial ROS generation is likely much less than in myocytes.
However, studies have indicated that vascular and endothelial cell
mitochondria can represent a significant source of ROS, which
in addition to cytosolic NAD(P)H oxidase (Nox) and xanthine
oxidase-dependent ROS sources, contribute to the vicious cycle of
ROS production and subsequent endothelial dysfunction (Dikalova
et al., 2010). Increased vessel wall Nox-derived O2− is indeed an
important determinant of endothelial dysfunction in experimental
angiotensin II (AII)-induced hypertension and genetic hypertension (Cave et al., 2006). Moreover, in a recent study, Dikalova et al.
(2010) reported that endothelial cell mitochondria are the initial
sources of ROS in response to AII-stimulated vascular dysfunction,
whereas Nox is secondarily activated. This Nox-dependent ROS
production could lead to a pathological process of mitochondriaNox axis in a feed-forward loop of deleterious ROS production
(O’Connor and Gutterman, 2010).
It is evident that a loss of endothelial-derived NO bioavailability is a critical component in the etiology of vascular dysfunction and is an independent risk marker for future cardiovascular
complications. O2− inactivation of NO by the uncoupling of
NOS, contributes to vascular endothelial dysfunction. In addition
to its indirect actions through inactivation of NO , O2− also likely
exerts a direct action on vascular endothelium (Cave et al., 2006).
Increased endothelial O2− and the concomitant production of
ONOO− are likely to result in nitration of mitochondrial proteins
that cause further damage to the organelle. It has been proposed
that one of the major culprits in vessel damage is H2O2-mediated
damage of the ETC (O’Connor and Gutterman, 2010), in which
case reduction of H2O2 to H2O by antioxidants would help to ameliorate the damage. Damage to endothelial cell structure or function
is considered to be among the primary causes of atherosclerosis
(Davidson and Duchen, 2007) and other peripheral artery diseases
(Pipinos et al., 2006). mPTP opening is prominent in endothelial
cell-induced death leading to atherosclerotic lesions (Davidson and
Duchen, 2007), so the mPTP is a potential target for minimizing the
progression of atherosclerosis. In addition, endothelial cell mCa2+
overload, diminished levels of MnSOD activity, and decreases in
ETC complex activities, have all been implicated in the events that
lead to endothelial and vascular cell injury and death (Pipinos et al.,
2006; Davidson and Duchen, 2007).
A thorough understanding of the etiology of vascular dysfunction, specifically as it pertains to the role of mitochondria, may
enable development of improved therapies for vascular diseases.
Although treatment with antioxidants or with SOD mimetics has
been effective in reducing oxidative stress and improving endothelial
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function, the results from human studies have been singularly
disappointing (Cave et al., 2006; O’Connor and Gutterman, 2010).
For example, instead of using antioxidants that are not targeted
to sites of ROS (e.g., vitamins C and E), mitochondria-targeted
ROS scavengers or other “mitochondriotropic” agents (discussed
above) might be more effective (Cave et al., 2006; Dikalova et al.,
2010; O’Connor and Gutterman, 2010). Recent treatment strategies
that target mitochondrial sources of ROS over cytosolic sources of
ROS (O’Connor and Gutterman, 2010) have proven more effective
in dampening endothelial dysfunction and minimizing vascular
impairment (Dikalova et al., 2010). It is thought that the ability of
targeted delivery in this case would also minimize the potential for
untoward effects of other therapies that are less specific (Dikalova
et al., 2010).
Other potential strategies include pathways that regulate mitochondrial biogenesis. As noted above, resveratrol is one such agent.
Impaired mitochondrial endothelial cell function in a disease process, e.g., diabetes, may impair bioenergetics, which could underlie
a defect in endothelial paracrine factors essential for maintaining
vascular tone (Csiszar et al., 2009a). Resveratrol has been shown
to induce mitochondrial biogenesis in the aortas of diabetic mice
and to reduce mitochondrial ROS; this suggests the potential for
targeting endothelial mitochondria in metabolic diseases (Csiszar
et al., 2009a,b). Interestingly, recent studies have demonstrated the
presence of estrogen receptors on mitochondria and that estrogen
stimulates increase ATP production while reducing ROS generation
in cerebral arteries (Duckles et al., 2006). Estrogen also increases
transcription of mitochondrial genes that encode subunits of complex IV (Duckles et al., 2006). These effects could be significant in
certain age-related cardiovascular diseases such as stroke (Duckles
et al., 2006). Resveratrol and statin drugs also induce endothelial
NOS to restore endothelial NO levels appropriate for vasodilatation. This vascular response is central to the achievement of integrated increases or redistribution of blood flow among specific
vascular beds (Cave et al., 2006; Davidson and Duchen, 2007).
Potential for mitochondria-targeted strategies for the
failing heart

Heart failure progressively limits the pumping capacity of the heart
and endothelial and vascular dysfunction are important components in this process (Davidson and Duchen, 2007) because of
decreases in vascular diameter and compliance (coronary reserve)
which reduces tolerance to exercise (Cave et al., 2006). Chronic
heart failure occurs frequently as a consequence of longstanding
hypertension or ischemic heart disease (Cave et al., 2006) and is a
leading cause of morbidity and mortality in Western industrialized
countries. Despite extensive studies, the fundamental mechanisms
responsible for the development and progression of heart failure
have yet to be fully elucidated (Tsutsui et al., 2006). A growing body
of evidence supports a role for oxidative stress and redox signaling
in the pathophysiology of heart failure (Cave et al., 2006). Indeed
a number of recent studies have indicated that mitochondria are
central to the pathophysiologic mechanism of the failing heart.
Mitochondrial released ROS play a major role in mitochondrial
bioenergetic dysfunction and contribute to myocardial apoptosis, which with cell necrosis and fibrotic cell invasion, underlie
the anatomical progression of heart failure (Marin-Garcia and
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Goldenthal, 2008; Chen and Knowlton, 2010). Increased levels of
mitochondrial network fragmentation are also observed in damaged heart muscle, thus suggesting the significance of the mitochondrial reticular network in the etiology and progression of the
disease (Shen et al., 2007).
The inexorable loss of terminally differentiated cardiomyocytes
and the subsequent invasion of fibrotic tissue are pivotal to progression of heart diseases, especially ischemic and dilated cardiomyopathies and congestive heart failure (Shen et al., 2007). During failure
the heart decompensates because of an imbalance between energy
production and use that leads to a state of energy deficit (Camara
et al., 2010a). Abnormalities in energy transfer may occur in failing
cardiac muscle and correlate with clinical symptoms and mortality
(Murray et al., 2007). In general, the progression of heart failure
can be characterized by diminished energy metabolism, poor Ca2+
handling, ROS generation, and apoptotic cell death. Alterations in
mitochondrial function with dysregulation of mitochondrial biogenesis, and defects in ETC complexes I and III (Rosca et al., 2008),
have been long suspected in heart failure. Indeed, therapies aimed
at protecting mitochondrial function have shown some promise in
heart failure patients and animal models of heart failure (Murray
et al., 2007). For example, in mouse hearts exposed to chronic
systolic pressure overload induced by transverse aortic constriction,
the PGC-1α−/− knockout caused moderate but significant decreases
in MnSOD and TRX2, with subsequent increases in oxidative stress
markers, e.g., 4-HNE. Furthermore, treatment with the MnSOD
mimetic MnTMPyP significantly reduced the transverse aortic
constriction-induced left ventricular hypertrophy and dysfunction in PGC-1α−/− deficient mice (Lu et al., 2010).
The mitochondrial content and hence oxidative capacity of
cardiac muscle cells are diminished in heart failure (Garnier et al.,
2003). The result is limited work capacity in the failing heart due to
limited free mitochondrial energy (Ochiai et al., 2001; Gong et al.,
2003). Indeed, in mitochondria isolated from patients exhibiting
severe cardiomyopathies there is a significant decrease in state 3
respiration and a lower respiratory control index (Sharov et al.,
2000). Thus the altered metabolic pattern observed in heart failure
has a clear impact on the energetic state of the heart. The potential
consequences of a diminished energetic state include an impaired
ability of the heart to work and respond to acute and chronic
stresses (Camara et al., 2010b).
Although the idea of treating metabolic cardiac dysfunction is
not new, the targeting of mitochondria has garnered significant
interest recently. Cardiac metabolic homeostasis was summarized
near the beginning of this review. The failing heart is characterized by enhanced glycolysis, impaired pyruvate oxidation, and
reduced FA oxidation. Glycolysis generates pyruvate and if this
pyruvate cannot be utilized by PDH to fuel OxPhos only 2 ATP
molecules/glucose are realized. As discussed above, PDH is regulated by multiple factors including PDH kinase (PDK) and PDH
phosphatase (Beadle and Frenneaux, 2010); PDK, whose activity is low depending on NADH and acetyl-CoA coming from FA
β-oxidation (Nediani et al., 2011), is thus a key regulator of glucose
oxidation. Activated PDK phosphorylates and inhibits PDH and
thereby blocks pyruvate uptake into mitochondria and prevents its
oxidation. During acute ischemia, there is also a block at the level
of PDH. It was reported that activation of PDK can lead to right
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ventricular dysfunction and that reduction of enzyme function
not only restores right ventricular function, but also enhances glucose oxidation (Piao et al., 2010). Selected and precise control of
these mitochondrial metabolic enzymes and glucose transporters
(GLUT) represent possible therapeutic targets to modulate substrate utilization (Beadle and Frenneaux, 2010). Indeed, a variety of
metabolically targeted therapies have already been applied clinically
in an attempt to improve cardiac metabolic function in human
heart failure. These include, but are not limited to, an approach
to reverse abnormal metabolism by stimulating PDH by inhibiting PDK directly with dichloroacetate (DCA) and leelamine HCl,
or indirectly with ranolazine and trimetazidine (Cadoudal et al.,
2008). DCA can restore ∆Ψm by inhibiting PDK and thereby activating PDH with a concomitant increase in intra-mitochondrial
acetyl-CoA (Archer et al., 2008) (Figure 1). DCA has been safely
used in children with inherited mitochondrial disorders (Bersin and
Stacpoole, 1997) and lactic acidosis (Archer et al., 2008).
As discussed earlier, the adult healthy heart derives most of its
energy from oxidation of FA, and FA oxidation strongly inhibits glucose oxidation; this is because acetyl-CoA derived from FA
β-oxidation inhibits PDH activity so glycolysis is halted (Beadle and
Frenneaux, 2010). Thus, by maintaining acetyl-CoA removal by FA
β-oxidation, upregulation of PDK facilitates the continuous uptake
of long chain fatty acyl-CoA (transformed from malonyl-CoA) into
the mitochondrial matrix for oxidation, preventing their accumulation in the cytoplasm, where they would exert toxic effects on cardiac function (Nediani et al., 2011). However, despite its potential
benefits, attempting to control β-oxidation of FA has numerous
drawbacks and limitations. For example, although β-oxidation of
FA produces more energy per carbon than glycolysis, it requires a
higher consumption of O2 (Nediani et al., 2011).
In heart failure there appears to be a downregulation of genes
controlling mitochondria biogenesis and of enzymes involved in
FA oxidation (Nediani et al., 2011). The mitochondrial content
and hence oxidative capacity of both skeletal and cardiac muscle
cells are diminished in heart failure (Camara et al., 2010a), i.e.,
“starvation in the land of plenty.” However, the concept that FAs
are bad for contractile function in the failing or diseased heart is
challenged by other studies. For example, recent reports show that
decreased FA oxidation during heart failure could be maladaptive
(Cheng et al., 2004), and that increasing FA availability aids the
failing heart (Duda et al., 2008; Muoio and Newgard, 2008). In
this case, patients with dilated cardiomyopathy challenged with
acute FA depletion demonstrated enhanced glucose oxidation but
decreased cardiac work and efficiency (Tuunanen et al., 2006a,b). A
crucial distinction between physiological and pathological cardiac
remodeling (the later being a process ultimately progressing to
heart failure) is the ability of the heart to match workload with an
increased ATP production (see earlier discussion).
In an attempt to increase the efficiency of energy production
in the failing heart, several drugs that inhibit FA oxidation and
thereby allow glycolysis and SLP have been subject to testing. For
example, etomoxir, originally developed as an anti-diabetic drug
to switch energy metabolism from FA to glucose by inhibiting the
FA transporter CPT1, has been clinically tested for treatment of
chronic heart failure (Wolf, 1992; Kerner et al., 1994). However,
long-term use of this drug is associated with toxicity and ironically,
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heart failure (Stanley et al., 1997). The CPT1 inhibitors o
 xfenicine
and perhexiline have been shown to delay the development of
terminal heart failure and attenuate the adverse hemodynamic
changes (Abozguia et al., 2006). These drugs are known to activate
expression of genes encoding key mitochondrial proteins involved
in cardiac energy metabolism. For example, oxfenicine in heart
failure has been shown to down regulate the transcription of CPT1
and to prevent a decrease of TCA cycle enzyme activity (Abozguia
et al., 2006). Other drugs such as trimetazidine, which blocks the
key enzyme in FA oxidation, as well as ranolazine, are reported to
directly attenuate β-oxidation enzyme activity and potentially other
metabolic enzymes (Stanley et al., 1997; Bristow, 2000). Hence, the
process of metabolic remodeling could serve as a target to restore
metabolic flexibility and thereby facilitate improved myocardial
contractility (Taegtmeyer et al., 2005; Kolwicz and Tian, 2009).
This approach of optimizing energy substrate preference in the
heart is a new and potentially promising approach to treat cardiac
dysfunction associated with angina pectoris (Lam and Lopaschuk,
2007) and other cardiac abnormalities.
As noted above, mitochondria isolated from failing hearts display
increased ROS production in association with signs of oxidative
stress-related damage due to accumulation of lipid peroxidation
by-products and mutations or deletions of mtDNA (Ide et al., 2001;
Burelle et al., 2009). Other studies show decreases in the expression
and activity of catalase and MnSOD in heart failure (Laskowski
and Russell, 2008). Evidence also shows increased mitochondrial
membrane permeability and a consequent increase in release of
cytochrome c and down stream pro-caspases; all of these factors
indicate that the mitochondria-induced apoptotic pathway is a
requirement to cardiomyocyte death by apoptosis (Burelle et al.,
2009). From these observations the importance of decreasing oxidative and nitrosative stress by decreases in ROS and RNS generation
and the successful use of antioxidant therapy in heart failure can
not be overstated (Tsutsui et al., 2006). Indeed, ROS and RNS scavengers have been shown to attenuate the structural and functional
abnormalities associated with heart failure in a rat model (Li et al.,
2009). In that study Li et al. (2009) reported that the antioxidant
α-lipoic acid attenuated mitochondria-dependent apoptosis in diabetic cardiomyopathy. In addition, UCP levels are often decreased
in animal models of heart failure and in human clinical samples
(Laskowski and Russell, 2008). Targeting the UCPs therefore may
represent a promising approach to managing heart failure.
Potential for treating mitochondria in cardiac I/R injury

Some aspects of this subject were discussed in other sections
and also were discussed extensively in two recent review articles
(Chen et al., 2007; Camara et al., 2010b) so this topic will be only
briefly addressed. I/R has been shown to result in mitochondrial
dysfunction, so the importance of mitochondria as both targets
and mediators of I/R injury is well recognized (Chen et al., 2007).
During ischemia, ETC complex activities and the functions of
ANT and CPT1 are depressed as a result of damage to cardiolipin
and increased H+ leak, thereby compromising ∆Ψm and ATP supply (Paradies et al., 2009). During ischemia, anaerobic glycolysis
partially generates the needed ATP with a concomitant increase
in intracellular acidosis, but eventually impaired ATP-dependent
ion pumps that are required to maintain ion homeostasis fail.
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Intracellular acidosis drives the Na+/H+ exchanger and this leads
to increased intracellular [Na+] and a subsequent increase in intracellular [Ca2+] after activation of the Na+/Ca+ exchanger in reverse
mode. These alterations in cytosolic [Na+] and [Ca2+] also induce
dysregulation of ion homeostasis in mitochondria resulting in
mCa2+ overload (discussed above), which in turn results in mitochondrial depolarization that helps to limit further Ca2+ uptake via
the CaU. Upon reperfusion however, repolarization of ∆Ψm coupled
with increased cytosolic Ca2+ leads to a further increase in mCa2+
load via the CaU. With recovery of matrix pH (less acidic), low ATP
levels, and a high Pi, on reperfusion, opening of the mPTP can occur.
Thus, CsA and other mPTP inhibitors may lead to cardioprotection, but only if administered on reperfusion (Duchen, 2004). Five
potential strategic approaches to protect mitochondria against cardiac I/R injury are given in the following five sections (not discussed
in our previous comprehensive review article (Camara et al., 2010a).
Attenuation of mitochondrial bioenergetics as a potential
strategy to protect against I/R injury

Many studies now show that increases in mitochondrial ROS and
m[Ca2+] occur nearly simultaneously during ischemia (Vanden
Hoek et al., 1997; Kevin et al., 2003; Riess et al., 2004; Stowe et al.,
2006; Camara et al., 2007; Aldakkak et al., 2008a,b) and that their
reduction on reperfusion are indicative of protection. A pioneering
study by Ganote et al. (1976) showed that inhibiting mitochondrial respiration could decrease contraction band formation and
attenuate enzyme release during reoxygenation; they suggested
that resumption of mitochondrial metabolism during reoxygenation could initially lead to deleterious consequences (Ganote
et al., 1976). Either restriction of oxidative metabolism during the
early reperfusion period, use of a hypoxic reperfusate (Kasamaki
et al., 1997; Serviddio et al., 2005), or inhibition of ETC activity
(Ambrosio et al., 1993), attenuated mitochondrial and cardiac damage as evidenced by decreased cardiac function and accumulation
of oxidatively damaged lipids. In a recent insightful review, Burwell
and Brookes (2008) proposed the concept of “a more gradual wakeup of mitochondrial function” to protect the myocardium from a
burst of ROS and mCa2+ overload following I/R. This concept of
gradual awakening on reperfusion is based on the premise that
reversible inhibition of metabolism by blocking ETC complexes
and glycolysis, and the slow reintroduction of electrons to the ETC,
will reduce damage (Burwell and Brookes, 2008).
Many findings support the physiologic significance of excess
mitochondrial ROS production in cardiac injury during reperfusion (Chen et al., 2007). With knowledge of some of the endpoints
of cardiac injury there are now a variety of strategies to target mitochondria that are postulated to interrupt the link between mitochondrial damage during ischemia and mitochondria-mediated
damage during reperfusion. Interestingly, we have observed preliminarily that resveratrol, a ROS scavenger (Bastianetto et al., 2000),
is more effective in protecting against I/R injury when administered briefly on reperfusion, whereas ranolazine, the anti-anginal
agent believed to reversibly inhibit complex I (Wyatt et al., 1995),
was more effective against I/R injury when given briefly before
ischemia (Aldakkak et al., 2009). Consistent with our observation
with resveratrol in the isolated beating heart, Morin et al. (2003a)
reported that resveratrol was more effective when administered
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during reoxygenation in isolated brain mitochondria. These data
suggest drugs that scavenge ROS may be more protective when
administered on reperfusion, whereas blockers of ETC are more
effective when given just before ischemia. Thus a potentially effective combination may be the selective administration of the differently acting drugs either before or after ischemia.
Other viable strategies that may work by modulating mitochondrial bioenergetics include the use of putative K+ channel agonists
like NS1619 (discussed above) and uncouplers like DNP (Aldakkak
et al., 2010; Sedlic et al., 2010b). Sedlic et al. (2010b) reported
recently that isoflurane, like DNP, may protect cardiomyocytes in
part via a mild decrease in ∆Ψm, which attenuated ROS production
under stress and led to a delay in mPTP opening. Overexpression
of UCPs in mice as well as chemical uncoupling of mitochondria in
rats markedly reduced infarct volume following focal cerebral I/R
(Duckles et al., 2006). However, clinical use of chemical uncoupling
(e.g., DNP) has been limited by its toxicity (Camara et al., 2010b).
Modulation of TCA cycle function as a potential strategy to
protect mitochondria during I/R injury

It has been suggested that glycolytically derived ATP is preferentially
used to activate Ca2+ uptake into the ER by Ca2+ ATPase and to activate the Na+/K+ ATPase that prevents intracellular Na+ accumulation
during ischemia (Beadle and Frenneaux, 2010). As discussed earlier,
limited O2 availability during ischemia or hypoxia leads to a shift
to glucose metabolism from mitochondrial OxPhos to cytosolic
substrate level phosphorylation (SLP; anaerobic glycolysis); but
prolonged ischemia leads to accumulation of lactic acid and depletion of NAD+. To sustain glycolysis under prolonged anaerobic conditions, lactate is excreted from the cell as a waste product. In this
scenario, when mitochondrial function is compromised and ∆Ψm is
reduced as in I/R, F0/F1 ATP synthase acts in reverse thereby hydrolyzing ATP in an attempt to reestablish ∆Ψm. In this case cytosolic
ATP is consumed to pump H+ out of the matrix to attempt to restore
∆Ψm; however, this is counterproductive for ATP-dependent cellular processes, e.g., contraction/relaxation of myofibrils and for
establishing cellular ionic homeostasis. In addition, restoration of
∆Ψm may cause further matrix Ca2+ accumulation, which could lead
to the perpetual and vicious cycle of cellular injury.
A novel concept in mitochondria-mediated cytoprotection is
that enhanced SLP within the matrix (in contrast to cytosolic SLP
from pyruvate) represents an endogenous rescue mechanism that
supports the reversal of the F0F1 ATP synthase to maintain ∆Ψm
while preserving cytosolic ATP. The matrix contains several enzyme
sites capable of SLP; these include α-ketoglutarate dehydrogenase
(Schwimmer et al., 2005) and succinyl-CoA synthase (SULCA).
SUCLA is an enzyme that catalyzes the reversible conversion of
succinyl-CoA and ADP or GDP to ATP or GTP (Kibbey et al.,
2007; Phillips et al., 2009). Hence, this could represent a source
of ATP during ischemia, primarily by SLP (Camara et al., 2010a).
Therefore, activation of these pathways could be crucial in periods
of energy deprivation when complex V reverts to ATP consumption
to maintain ∆Ψm as observed during I/R. In this way, cytosolic ATP
levels from glycolysis might be preserved for maintaining the operation of ATP-dependent ion exchangers, e.g., Na+/K+ ATPase and
Ca2+ ATPase, needed to maintain cellular cytosolic ion g radients,
while reverse ATP synthase at complex V supports, at least in part,
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the ∆Ψm. Therefore, cells may be salvaged as long as matrix SLP
is able to provide ATP for use by complex V and by limiting the
consumption of cytosolic ATP. Increasing the generation of matrix
SLP may be a worthwhile, but temporary, strategy to mitigate mitochondrial dysfunction at times of impaired OxPhos. For example,
overexpression or stimulation of SUCLA at a time of severe energy
deficit may provide the needed ATP for mitochondrial preservation
while sparing cytosolic ATP. Indeed, the putative mitoKATP channel
agonist diazoxide may in part mediate protection by facilitating
the binding of IF1, an endogenous regulator of F0F1 ATP synthase
activity. Upon binding to complex V, IF1 blocks ATP synthasemediated ATP hydrolysis. In this way diazoxide could contribute
to cardioprotection by preserving ATP during ischemia (Szewczyk
et al., 2010).
Modulation of mitochondrial ROS generation as a potential
protective strategy during I/R injury

Some aspects of this topic have been discussed earlier. Nonetheless,
the association of O2− generation with I/R injury has made the
development of antioxidants for therapeutic uses a plausible goal
(Camara et al., 2010b). Therapeutic strategies to limit the rate of
mitochondrial ROS generation or to increase the rate of ROS scavenging may be useful adjuvants to conventional therapies designed
to protect the heart from I/R damage. We reported that administering a cocktail of mitochondrial scavengers (MnTBAP + glutathione
+ catalase) prior to cold cardiac ischemia and warm reperfusion
provided protection against mCa2+ overload and ROS production and that this helped to preserve cardiac function (Camara
et al., 2007). Artificial antioxidants such as SOD mimetics may be
more potent than their natural counterparts, but their usefulness
in clinical trials has not been determined (Muravchick and Levy,
2006; Schapira, 2006). Needless to say, mitochondria-targeted ROS
scavengers, such as ubiquinone and vitamin E, have shown some
efficacy against cell damage associated with I/R injury. However,
clinical trials using α-tocopherol (vitamin E), ascorbate (vitamin
C), CoQ, and α-lipoic acid, have so far yielded ambiguous results
(Camara et al., 2010b).
Modulation of gaseous signaling molecules as a potential
protective strategy during I/R injury

In addition to the endogenous enzymes synthesizing or releasing NO and O2− , carbon monoxide (CO) and hydrogen sulfide
(H2S) gases are also present in small amounts; they share many of
the “friends-and-foe” characteristics of ROS and RNS (Baumgart
et al., 2009). The role of NO has been discussed before in several
sections and a detailed discussion of its role in cardioprotection
can be found in our recent comprehensive articles (Stowe and
Camara, 2009; Camara et al., 2010b), and will not be discussed
further here. As gaseous second messengers, they also share some
common biological targets, for example heme-proteins and KATP
channels (Burwell et al., 2009). At physiologic concentrations CO
and H2S may help to protect against many pathologic conditions
including cardiovascular diseases. At higher concentrations, however, these gases are toxic with deleterious effects on the cell (Lefer,
2007). A recent review article discusses the interplay between the
gases at the level of mitochondrial complexes (Cooper and Brown,
2008; Calvert et al., 2010).
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H2S may be endogenously synthesized in small amounts in
the heart, and like NO , it competitively inhibits O2 binding to
complex IV, an effect that could promote myocardial cell survival
during I/R (Bian et al., 2006; Lefer, 2007). Considered a poisonous
gas at high concentrations, H2S is being recognized as an inorganic
mediator with a potentially broad therapeutic potential (Baumgart
et al., 2009). It could develop as a useful mediator of cardiovascular homeostasis and cytoprotection. For example, H2S has been
implicated in IPC cardioprotection via activation of both mitoKATP
and sarcolemmal KATP channels; the exogenous H2S donor, NaHS,
was shown to increase cell viability and to improve cardiac function during I/R (Bian et al., 2006); 5-HD abolished the protective
effects of H2S (Baumgart et al., 2009). Another possible mechanism
of protection by H2S is scavenging of ROS, by which it is believed
to reduce arrhythmias during I/R (Bian et al., 2006). Similar cytoprotective effects against oxidative stress have been observed in
the brain where H2S protected neurons from oxidative stress by
increasing the production of the antioxidant GSH (Kimura and
Kimura, 2004). As a reducing agent, H2S may react with H2O2 and
in this way scavenges ROS (Kimura and Kimura, 2004). However,
the preferred route of therapeutic administration of H2S remains
unclear.
CO, like NO and H2S, reversibly binds to the reduced complex
IV where it competes with O2; CO may block O2 binding at complex
IV in vivo (Zuckerbraun et al., 2007) and lead to cardioprotection
against I/R injury, whereas Na azide, a cyanide containing compound which also inhibits complex IV, was found to be ineffective
in protecting the heart (Chen et al., 2010). Taken together, Chen
et al. (2010) posits that there are inconsistencies regarding potential cardioprotection provided by complex IV inhibition. It may
be that CO has other cytoprotective effects other than binding to
complex IV. Indeed, in I/R, CO has been reported to increase ATP
and GTP levels to maintain efficient energy utilization within the
heart during the ischemic period (Lavitrano et al., 2004), which
correlates to a greater ease by which the heart can generate force on
reperfusion and minimize the incidence of fibrillation. Although
the cause–effect relationship of CO with nucleotide concentrations
is unclear, this metabolic modulation to protect the heart may be
analogous to SLP-induced protection discussed previously. CO
could also provide protection by preserving mitochondrial NADH,
i.e., decrease oxidation of the reduced redox state, via its action
on the ETC. The increase in NADH may reflect the possibility of
decreased O2 consumption, resulting in an overall lower metabolic
state and a reduction in appearance in apoptotic markers (Lavitrano
et al., 2004). Endogenous CO generated by overexpression of heme
oxygenase (HO)-1 was shown to stimulate MnSOD and generate
H2O2, which in turn activated signaling molecules that lead to mitochondrial biogenesis (Piantadosi et al., 2008) and cardioprotection.
Interestingly, hydrogen gas (H2) has been proposed as a potential
therapeutic agent with both anti-apoptotic and antioxidant features
(Wood and Gladwin, 2007). Inhaled H2 gas can reach its target
rapidly and provide protection against I/R (Hayashida et al., 2008).
Thus H2 gas may be a promising strategy to mitigate I/R injury
(Hayashida et al., 2008); but its use is limited by its highly explosive
nature (Baumgart et al., 2009). All together, these studies provide
a rationale for targeting mitochondria with low concentrations
of gases that compete with O2 at complex IV, although as noted,
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this may also be detrimental if administered at the inappropriate
time and concentration. The defined physiological role of these
gases makes them potential pharmacological candidates to target
mitochondria in the treatment of cardiovascular diseases. Specific
overexpression of those enzymes that generate some of these gases
could be a feasible approach to mitigating some disease states, particularly in high energy consuming organs.
Protecting cardiac mitochondria with near infrared light
during cardiac I/R injury

Mitochondria are sensitive targets for therapy with red light. Low
energy photon irradiation by light in the far red to near infrared
spectral range (630–1000 nm; NIR) emitted using low energy lasers
or light emitting diode arrays (LED) has been found to provide
good cardioprotection. In experimental models of myocardial infarction low energy lasers (803 nm) reduced infarct size 50–70%
4–6 weeks after permanent occlusion of the left descending coronary artery in rats and dogs (Oron et al., 2001). Low-level laser
application up-regulated inducible NOS and vascular endothelial
growth factor and these changes were associated with cardioprotection and enhanced angiogenesis (Tuby et al., 2006).
We demonstrated recently that acute application of NIR
(670 nm) at the point of reperfusion or reoxygenation resulted in
a significant decrease in infarct size, or protection of cardiomyocytes, respectively (Lohr et al., 2009; Zhang et al., 2009). Indices
of apoptosis, including caspase 3 activity, annexin binding, and
the release of cytochrome c from mitochondria into the cytosol,
were decreased after NIR treatment. NIR increased NO levels in
cardiomyocytes, and the protective effect of NIR was completely
reversed by the NO scavenger carboxy-PTIO and by oxyhemoglobin, but only partially blocked by the NOS inhibitor l-NMMA.
Mitochondrial metabolism, measured by ATP synthase activity, was

increased by NIR, and NO -induced inhibition of O2 consumption with substrates for complex I or complex IV was reversed by
exposure to NIR (Zhang et al., 2009).
Mitochondrial cytochromes have been proposed as photoacceptors for NIR light energy and mitochondrial redox changes have
been proposed as potential mediators of the biological effects of
NIR (Hallen et al., 1993; Hallen and Brzezinski, 1994; Wong-Riley
et al., 2005). The action spectrum of NIR light for stimulation of
cytochrome c oxidase activity parallels the NIR absorption spectrum of the oxidized form of complex IV (Karu et al., 2004). NIR
increased mitochondrial metabolism, including cytochrome c oxidase activity and elevated cellular ATP content (Karu et al., 1995).
Interestingly, NIR reversed the toxic effects of KCN, an irreversible
inhibitor of complex IV, in primary neurons (Wong-Riley et al.,
2005) and improved retinal function in an animal model of mitochondrial dysfunction induced by methanol-derived formate, a
reversible cytochrome c oxidase inhibitor (Eells et al., 2004).
The mechanism behind this metabolic enhancement of challenged mitochondria through NIR remains controversial. Changes
in the redox properties and acceleration of e− transfer at the center
of complex IV have been suggested as well as enhanced NO release
(Karu, 2008). The direct actions of light reversal of NO mediated
complex IV inhibition, with its resulting increase in respiration and
ATP production, could be effective in ameliorating reperfusion
injury. In contrast, we demonstrated recently, both in purified

www.frontiersin.org

Targeting mitochondria in cardiac ischemia

s ystems and in myocardium, that NIR can release NO from nitrosyl
hemoglobin or myoglobin (Lohr et al., 2009). NIR-induced release
of NO might contribute to protection from reperfusion injury
through actions on mitochondria and NO -dependent signaling
pathways. As noted above, an inhibitory effect of NO on ETC,
particularly complexes I and IV, has been suggested to increase
cellular viability in myocardial I/R injury by decreasing ROS generation during reperfusion (Hendgen-Cotta et al., 2008). Although
NOS produces the bulk of NO , there is increasing interest in

NOS independent generation of NO in vivo, particularly during
hypoxia or anoxia, where low O2 tensions limit NOS activity and
when the nitrite reductase activity of myoglobin and hemoglobin
are highest (Gladwin and Kim-Shapiro, 2008). Interventions such
as NIR that can increase NO bioavailability in a localized manner
have significant therapeutic potential against heart disease without
systemic side effects. Thus, the effect of NIR on the heart, and
specifically on mitochondria, may depend on a delicate balance
between stimulation and attenuation of mitochondrial metabolism.

Limitations and conclusion
As mitochondria are the most prominent source of intracellular ROS
and RNS, they have been implicated in both defensive and offensive aspects of the cell; but selective targeting of mitochondria with
mitochondrial-targeted agents is likely to pose a quandary. Targeting
mitochondria for therapeutic purposes poses a dilemma of how
to protect, while at the same time, preserve the normal aspects of
cellular functions that maintain viability. This quandary has been
observed by Muravchick and Levy (2006) in a recent review article
noting that, “therapeutic strategies that suppress or block the effects
of putative pro-apoptotic agents may produce unintended interruptions of other cell functions and actually compromise viability.”
The aim of this review was to provide and summarize a growing
body of evidence that mitochondria are intimately involved in cell
survival and cell death and indeed in the etiology of cardiovascular
diseases. This role renders mitochondria as unique targets for pharmacological and non-pharmacological interventions. Currently,
most efforts along these lines focus on preventing the mitochondrial oxidative damage that arises from ischemic or hypoxic conditions. Examples of mitochondria-targeted maneuvers include:
decreasing mPTP opening; decreasing ∆Ψm to reduce O2− production; moderate inhibition of complexes upstream of complex IV
to reduce ROS production from complex III; limiting cytosolic
ATP consumption during cell distress with increased matrix SLP;
and increasing signaling gas molecules with, for instance, photobiomodulation therapy. In addition, mitochondria are targets for
gene therapy in case of diseases caused by mutations of mtDNA
or nuclear DNA (Wojtczak and Zablocki, 2008). The timing, conditions of drug deliver, and drug concentration, will be crucial
in assessing whether the treatment is beneficial or deleterious to
mitochondrial function during and after cell injury.
It is evident that much attention has been focused on developing mitochondria-targeted drugs that may accumulate in mitochondria without affecting other parts of the cell. Therefore,
novel approaches with more tissue specific mitochondria-targeted
approaches or interventions that will furnish a greater efficacy and
selectivity with fewer undesirable effects are being pursued. Use
of mitochondriotropic drugs seems to be the most promising
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approach to prevent or treat mitochondrial diseases associated with
cardiovascular dysfunction. However, due to lingering concerns in
drug delivery to appropriate organs and possible untoward effects,
these techniques will need to be improved and refined over time.
Lastly, effective genetic and molecular approaches to provide bettertargeted delivery of desired therapeutic agent, although promising,
remains at best a rudimentary notion to date (Camara et al., 2010b).
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